Fatty Liver Disease

Type 2 Diabetes Accelerates Liver Fibrosis in Chronic Hepatitis B with Fatty Liver: Hepatology | May 2026

Introduction: Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with concurrent hepatic steatosis. Why was this study needed? The coexistence of CHB, fatty liver, and T2DM is becoming increasingly common. The impact of diabetes on liver fibrosis in CHB remains poorly understood. Viral and metabolic factors may contribute differently to liver injury. Better risk stratification is needed for patients with dual liver disease. Understanding these interactions may improve long-term management. Results: Type 2 diabetes independently increased the risk of significant liver fibrosis in treatment-naïve CHB patients with hepatic steatosis. HBeAg positivity was primarily associated with hepatic inflammation, whereas higher BMI predicted more severe hepatic steatosis, highlighting distinct roles of viral and metabolic factors. These findings demonstrate that diabetes contributes to fibrosis progression independently of other metabolic syndrome components. Clinical Impact: This international study reinforces the need for a dual therapeutic approach in CHB patients with fatty liver. While antiviral therapy remains essential for viral control, aggressive management of diabetes may be equally important to slow fibrosis progression and improve long-term liver outcomes. Bottom Line: Type 2 diabetes is an independent driver of liver fibrosis in chronic hepatitis B patients with hepatic steatosis. Optimal management should address both viral replication and metabolic risk factors, particularly diabetes, to reduce the risk of progressive liver disease.

A Novel Gut-Targeted Therapy for MASH (DT-109): Journal of Clinical Investigation | July 2026

Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring the gut–liver axis and reversing MASH. Why was this study needed? Current therapies only partially address MASH progression. Gut barrier dysfunction is increasingly recognized as a key driver of MASH. Ammonia-producing gut bacteria may contribute to liver inflammation and fibrosis. Novel therapies targeting the gut–liver axis are urgently needed. Safe treatments with both hepatic and cardiometabolic benefits are desirable. Results: DT-109 reversed MASH in animal models by restoring intestinal barrier integrity and reducing liver inflammation. The drug suppressed Clostridium perfringens, reduced intestinal ammonia production, and prevented the systemic translocation of harmful microbial products that promote hepatic inflammation. In non-human primates, DT-109 significantly improved liver inflammation and MASH severity, suggesting strong translational potential. In addition, previous studies suggest potential cardiovascular benefits, including reduced atherosclerosis and vascular calcification. Clinical Impact: DT-109 introduces a novel therapeutic concept by targeting the gut microbiome and intestinal barrier rather than the liver alone. If confirmed in human trials, this approach could represent a new generation of gut-directed therapies for MASH, with potential benefits extending to cardiovascular disease and other disorders linked to gut barrier dysfunction. Bottom Line: DT-109 treats MASH by repairing the gut–liver axis rather than directly targeting the liver. By restoring intestinal barrier function and reducing ammonia-producing gut bacteria, it represents a promising new therapeutic strategy that now warrants clinical evaluation in humans.

DT-109- A Novel Gut-Targeted Therapy for MASH: JCI | July 2026

Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring the gut–liver axis and reversing MASH. Why was this study needed? Current therapies only partially address MASH progression. Gut barrier dysfunction is increasingly recognized as a key driver of MASH. Ammonia-producing gut bacteria may contribute to liver inflammation and fibrosis. Novel therapies targeting the gut–liver axis are urgently needed. Safe treatments with both hepatic and cardiometabolic benefits are desirable. Results: DT-109 reversed MASH in animal models by restoring intestinal barrier integrity and reducing liver inflammation. The drug suppressed Clostridium perfringens, reduced intestinal ammonia production, and prevented the systemic translocation of harmful microbial products that promote hepatic inflammation. In non-human primates, DT-109 significantly improved liver inflammation and MASH severity, suggesting strong translational potential. In addition, previous studies suggest potential cardiovascular benefits, including reduced atherosclerosis and vascular calcification. Clinical Impact: DT-109 introduces a novel therapeutic concept by targeting the gut microbiome and intestinal barrier rather than the liver alone. If confirmed in human trials, this approach could represent a new generation of gut-directed therapies for MASH, with potential benefits extending to cardiovascular disease and other disorders linked to gut barrier dysfunction. Bottom Line: DT-109 treats MASH by repairing the gut–liver axis rather than directly targeting the liver. By restoring intestinal barrier function and reducing ammonia-producing gut bacteria, it represents a promising new therapeutic strategy that now warrants clinical evaluation in humans.

Tirzepatide vs SGLT2i in MASLD: Hepatology International | July 2026

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have been limited. This large propensity-matched study compared these therapies in routine clinical practice. Why was this study needed? Head-to-head real-world comparisons between tirzepatide and SGLT2 inhibitors are lacking. MASLD requires therapies that improve both hepatic and cardiometabolic outcomes. Long-term clinical outcome data beyond weight loss are limited. Real-world evidence is needed to complement randomized clinical trials. Better treatment selection could improve survival and reduce liver-related complications. Results: Tirzepatide significantly reduced all-cause mortality, hospitalizations, major cardiovascular events, and major adverse liver outcomes compared with SGLT2 inhibitors. These clinical benefits were observed at 1 year and remained consistent through 3 years of follow-up. The findings suggest that tirzepatide may provide broader cardiometabolic and hepatic protection than SGLT2 inhibitors in patients with MASLD. Clinical Impact: This large real-world study supports tirzepatide as a highly effective therapeutic option for patients with MASLD and metabolic comorbidities. Beyond weight reduction and glycemic control, tirzepatide appears to improve both liver-related and cardiovascular outcomes, reinforcing its emerging role in the comprehensive management of MASLD. Bottom Line: Tirzepatide outperformed SGLT2 inhibitors across multiple clinically meaningful outcomes in patients with MASLD. These findings strengthen the growing evidence supporting tirzepatide as a preferred metabolic therapy for patients with fatty liver disease and associated cardiometabolic risk, while awaiting confirmation from prospective randomized trials.

Early Weight Regain After GLP-1 RA Discontinuation: Diabetes, Obesity and Metabolism | July 2026

Introduction: GLP-1 receptor agonists (GLP-1RAs) have revolutionized obesity treatment, producing substantial weight loss and cardiometabolic benefits. However, many patients discontinue therapy because of cost, adverse effects, or limited access, and weight regain frequently follows. This review summarizes current evidence on the mechanisms of post-GLP-1 weight regain and explores emerging treatment de-escalation strategies. Why was this review needed? Weight regain after stopping GLP-1RAs is common and poorly understood. There is limited guidance on how to safely discontinue GLP-1 therapy. The biological mechanisms driving rebound weight gain remain incompletely defined. Strategies to minimize early weight regain are urgently needed. Evidence is emerging that gradual treatment de-escalation may be preferable to abrupt discontinuation. Key Takeaways: Most weight regain occurs within the first few months after stopping GLP-1RA therapy, making this a critical period for intervention. Weight regain is driven by the return of appetite, increased hunger hormones (particularly ghrelin), and loss of pharmacologic appetite suppression. Improvements in blood glucose, blood pressure, and lipid profile also gradually diminish after treatment cessation. Abrupt discontinuation may create a biological mismatch between increased appetite and the sudden loss of GLP-1 activity, accelerating weight regain. Emerging evidence suggests that lower-intensity maintenance therapy may better preserve weight loss than abrupt treatment withdrawal. The role of structured dose tapering remains promising but has not yet been confirmed in prospective clinical trials. Clinical Impact: Obesity should increasingly be viewed as a chronic disease requiring long-term management rather than a condition treated with short-term pharmacotherapy. Patients discontinuing GLP-1RAs should receive close follow-up, lifestyle support, and individualized treatment plans during the early post-cessation period when the risk of weight regain is greatest. Bottom Line: Weight regain after GLP-1RA discontinuation is substantial and occurs predominantly during the early months after stopping therapy. Until stronger evidence becomes available, gradual treatment de-escalation or maintenance strategies may represent a more rational approach than abrupt discontinuation.

Incretin-Based Therapy for MASH: Metabolic Target Organ Damage | July 2026

Introduction: The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing promise in resolving steatohepatitis and slowing fibrosis progression, raising the question of whether dual-target incretin therapies may outperform GLP-1 receptor agonists alone. Why was this review needed? With multiple incretin-based agents now available or in development, clinicians need to understand whether dual agonists offer meaningful advantages over GLP-1 monotherapy and how they compare with other approved therapies such as resmetirom. What did the review show? GLP-1 receptor agonists and dual incretin therapies consistently achieve high rates of MASH resolution. Semaglutide significantly improved both steatohepatitis resolution and fibrosis in phase III studies. Dual agonists such as tirzepatide, survodutide, and pemvidutide target complementary metabolic pathways and may provide greater reductions in hepatic fat and body weight. In the IMPACT phase II trial, pemvidutide achieved MASH resolution in over half of treated patients but did not significantly improve fibrosis after only 24 weeks. Improvements in liver fat, liver enzymes, and several non-invasive fibrosis biomarkers were observed with pemvidutide. Gastrointestinal adverse events remained the most common side effects and were generally manageable. Longer-duration studies are needed to determine whether early metabolic improvements translate into meaningful fibrosis regression. Clinical Impact: Incretin-based therapies are becoming a major pillar of MASH treatment. Dual-target agents may provide additional metabolic benefits beyond GLP-1 monotherapy, but their long-term impact on fibrosis, treatment duration, and combination strategies remains to be established. Take-Home Message: Incretin therapies are reshaping the treatment of MASH. While dual-target agents appear biologically promising and achieve high rates of steatohepatitis resolution, whether two mechanisms are truly better than one for reversing liver fibrosis will require longer-term phase III evidence.

Metabolic Drivers of MASLD and MASH: Diabetologia | June 2026

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are now recognized as systemic metabolic diseases rather than isolated liver disorders. This review integrates current knowledge on how hormonal, metabolic, inflammatory, and fibrotic pathways interact to drive disease progression. Why was this review needed? Despite major advances in understanding MASLD, the mechanisms linking obesity, insulin resistance, adipose dysfunction, and chronic inflammation to progressive liver fibrosis remain incompletely integrated. A comprehensive understanding is essential for developing precision therapies. What did the review show? Insulin resistance is the central metabolic driver of MASLD and MASH progression. Dysfunctional adipose tissue increases free fatty acid delivery to the liver, promoting hepatic steatosis and lipotoxicity. Imbalance between insulin and glucagon disrupts glucose and lipid metabolism, accelerating liver injury. Chronic glucotoxicity and lipotoxicity trigger hepatocyte injury and persistent low-grade inflammation (metaflammation). Crosstalk between adipose tissue, the gut, and the liver amplifies immune activation and disease progression. Activation of hepatic stellate cells is the key pathway leading to liver fibrosis. Sex hormones and the gut–liver–adipose axis contribute to disease heterogeneity and individual susceptibility. The review highlights multiple therapeutic targets across metabolic, hormonal, inflammatory, and fibrotic pathways. Clinical Impact: MASLD should be managed as a multisystem metabolic disease rather than a liver-specific disorder. Targeting insulin resistance, adipose dysfunction, hormonal imbalance, and chronic inflammation may help prevent progression to MASH and advanced fibrosis. Take-Home Message: MASLD and MASH result from complex interactions between metabolic dysfunction, hormonal imbalance, inflammation, and fibrosis. Understanding these interconnected pathways provides the foundation for precision medicine and the development of mechanism-based therapies that target disease progression rather than hepatic steatosis alone.

AREL1: A New Stellate-Cell Target in MASH Fibrosis: Nature Communications | June 2026

Integrated single-cell and single-nucleus RNA sequencing identified a distinct hepatic stellate cell population associated with MASH-related fibrosis. AREL1 emerged as a characteristic gene of this fibrogenic stellate-cell population and was selectively increased in MASH fibrosis. Hepatic stellate cells are central drivers of liver fibrosis, but current therapies do not directly and selectively suppress their disease-associated activation. Cholesterol increased AREL1 activity, providing a mechanistic link between the metabolic environment of MASH and stellate-cell activation. AREL1 promoted fibrosis through the AREL1–ILK axis, leading to activation of the PI3K–AKT signaling pathway. Stellate-cell-specific deletion of Arel1 markedly reduced liver fibrosis in male mouse models of MASH. The investigators also developed vitamin A–modified lipid nanoparticles to deliver Arel1-targeted therapy directly to hepatic stellate cells. Therapeutic knockdown of Arel1 using this targeted delivery system substantially improved MASH-related fibrosis in preclinical models. The study supports a precision antifibrotic strategy that targets a specific pathogenic stellate-cell state rather than broadly suppressing liver inflammation. The findings remain preclinical. Human safety, optimal dosing, durability, off-target effects, and efficacy across different fibrosis stages require further evaluation. The report is currently an unedited early-access manuscript, so details may change during final publication. Bottom line: AREL1 links cholesterol exposure to hepatic stellate-cell activation through ILK–PI3K–AKT signaling. Targeted AREL1 silencing may offer a new cell-specific therapeutic strategy for MASH-related liver fibrosis.

Ultra-Processed Foods, MASLD and Cognitive Ageing: Nutrients | June 2026

This review proposes a processing-centred gut–liver–brain axis, positioning MASLD as a metabolic amplifier between ultra-processed food exposure and cognitive decline. Ultra-processed foods are not simply high in sugar, fat, or salt; industrial processing disrupts the food matrix, accelerates eating, displaces fibre-rich microbial substrates, and introduces additives and processing-derived compounds. Higher ultra-processed food intake has been associated with hepatic steatosis, MASLD, cognitive impairment, stroke, and dementia-related outcomes, although causality remains unproven. Proposed mechanisms include gut microbial dysbiosis, impaired intestinal barrier integrity, metabolic endotoxaemia, altered bile acid signalling, hepatic lipotoxicity, insulin resistance, and systemic inflammation. The liver may amplify gut-derived signals and transmit inflammatory, vascular, endocrine, and metabolic effects to the brain. Altered FXR and TGR5 bile acid signalling provides a biologically plausible communication pathway connecting the microbiome, liver metabolism, and neuroimmune function. MASLD shares several drivers of cognitive aging, including obesity, diabetes, dyslipidaemia, endothelial dysfunction, and chronic low-grade inflammation. Ultra-processed foods may also promote passive overconsumption through rapid eating, hyperpalatability, altered texture, and reduced satiety. Many proposed pathways overlap with general cardiometabolic disease, making it difficult to isolate the independent effect of food processing itself. Current evidence is mainly observational and mechanistic; the review does not establish that ultra-processed foods directly cause dementia or that treating MASLD prevents cognitive decline. Clinically, replacing ultra-processed foods with minimally processed, fibre-rich foods may simultaneously support liver, metabolic, vascular, and cognitive health. Future studies should combine dietary substitution trials with liver imaging, microbiome and metabolomic profiling, bile acid and inflammatory biomarkers, neuroimaging, and longitudinal cognitive assessment. Bottom line: Ultra-processed foods may disrupt gut–liver–brain communication, with MASLD acting as a hepatic amplifier of metabolic and inflammatory signals relevant to cognitive aging. The concept is compelling but requires prospective mechanistic and intervention studies.

Updated Care Pathway for MASLD Risk Stratification : Gastroenterology | Jul 2026

Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) has emerged as one of the most prevalent chronic liver diseases worldwide, affecting nearly one-third of adults and a majority of individuals with type 2 diabetes. Beyond liver-related complications, MASLD is strongly associated with cardiovascular disease, reduced quality of life, and increased mortality. Recent advances in nomenclature, noninvasive diagnostics, and therapeutic options have necessitated an updated, practical framework for patient management. Problem Statement: Despite the growing burden of MASLD, many patients remain undiagnosed or are identified only after developing advanced fibrosis or cirrhosis. Variability in screening practices, limited access to specialist care, and uncertainty regarding risk stratification contribute to delayed diagnosis and suboptimal management. Clinicians require a structured and evidence-based approach that can be applied across primary care and specialty settings. Summary: This updated AGA Clinical Care Pathway provides a comprehensive framework for the identification, risk stratification, and management of patients with MASLD and metabolic dysfunction–associated steatohepatitis (MASH). Developed by a multidisciplinary international panel, the pathway incorporates recent advances in disease nomenclature, noninvasive fibrosis assessment, and therapeutic management. The document emphasizes that MASLD should be actively considered in patients with metabolic risk factors, particularly type 2 diabetes, obesity, and cardiometabolic disease. A central focus of the pathway is the early identification of patients at risk for advanced fibrosis using noninvasive tests, allowing efficient triage and reducing unnecessary specialist referrals. The updated recommendations also reinforce the importance of comprehensive cardiometabolic risk management, recognizing cardiovascular disease as the leading cause of mortality in this population. In addition, the pathway integrates evolving evidence regarding pharmacologic therapies, obesity management, and multidisciplinary care models. Practical implementation strategies are provided to facilitate adoption across diverse healthcare settings and improve care coordination among primary care providers, endocrinologists, hepatologists, gastroenterologists, cardiologists, and obesity specialists. Overall, this updated pathway reflects the transition of MASLD from a liver-focused condition to a multisystem metabolic disease requiring coordinated risk-based management. By promoting earlier detection, standardized risk assessment, and targeted intervention, the pathway aims to improve liver-related outcomes while addressing the broader cardiometabolic risks faced by patients with MASLD.

PPARα Emerges as a Target in Lean MASLD : Acta Pharm Sin B | Jun 2026

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is traditionally linked to obesity, but an increasing number of patients develop significant hepatic steatosis despite having a normal body mass index. This entity, known as lean MASLD, presents a clinical paradox because affected individuals remain at substantial risk for progressive fibrosis, cardiovascular complications, and liver-related mortality. The mechanisms driving disease progression in this population are distinct and incompletely understood. Problem Statement: Unlike obesity-associated MASLD, lean MASLD cannot be fully explained by excess body weight alone. Factors such as visceral adiposity, dietary exposures, genetic susceptibility, and metabolic dysfunction contribute to disease development. Identifying the molecular pathways underlying lean MASLD is essential for developing targeted therapies tailored to this unique patient population. Summary: This review highlights peroxisome proliferator-activated receptor alpha (PPARα) as a central regulator in the pathogenesis of lean MASLD. PPARα plays a critical role in hepatic fatty acid oxidation, ketogenesis, and anti-inflammatory signaling, helping maintain metabolic homeostasis within the liver. The authors describe how multiple mechanisms—including aging-related signaling pathways, fructose-induced epigenetic changes, gut–liver axis disturbances, lipotoxicity, and genetic predisposition—converge to suppress PPARα activity, even in the absence of obesity. This impairment contributes to hepatic lipid accumulation and progressive metabolic dysfunction. The review further explores the limitations of currently available synthetic PPARα agonists in lean MASLD and highlights growing interest in natural product–derived modulators that simultaneously influence interconnected nuclear receptor pathways, including FXR and LXR. Particular attention is given to the PPARα–FGF21–ketogenesis axis as a key metabolic network with therapeutic potential. The authors propose that future treatment strategies should focus on selective hepatic reactivation of PPARα combined with biomarker-driven and genotype-guided patient selection. Overall, this review positions PPARα as a promising therapeutic target in lean MASLD and underscores the need for precision medicine approaches that recognize the distinct biological mechanisms underlying steatotic liver disease in non-obese individuals.

Who Should Receive Resmetirom?: CGH | April 2026

Resmetirom is the first FDA-approved therapy for patients with MASH/MASLD and stage F2–F3 fibrosis, creating an urgent need for reliable noninvasive methods to identify treatment candidates. This study evaluated whether currently proposed noninvasive treatment eligibility criteria accurately identify patients with biopsy-proven F2–F3 disease. The analysis included 1,281 patients from the HEPAmet registry with liver biopsy, elastography, metabolic profiling, and clinical characterization. Approximately 38% of patients had biopsy-confirmed F2–F3 fibrosis, representing the target population for treatment. Current expert panel recommendations and existing practice guidance performed poorly in real-world settings. Depending on the criteria used, only 39%–56% of eligible F2–F3 patients would have been identified for treatment. False-negative rates were particularly concerning, meaning that many patients who could potentially benefit from therapy would not receive treatment. Existing approaches also generated substantial false-positive rates, exposing some lower-risk patients to unnecessary therapy. The authors proposed a simplified two-step strategy. Step 1: FIB-4 ≥1.3 OR diabetes plus overweight/obesity even if FIB-4 is <1.3 Step 2: Liver stiffness measurement between 8 and 25 kPa This strategy improved identification of patients with clinically significant fibrosis and captured approximately 74% of the target F2–F3 population. The model also showed better diagnostic performance than currently proposed treatment algorithms. The findings emphasize that reliance on a single noninvasive marker is insufficient for treatment selection in MASLD. Combining metabolic risk factors with fibrosis assessment provides a more clinically useful approach. As additional therapies for MASLD become available, accurate noninvasive treatment selection will become increasingly important. The study supports moving toward pragmatic clinical algorithms that can be easily implemented in routine hepatology practice. Bottom line: Current noninvasive criteria for selecting patients for resmetirom miss a substantial proportion of biopsy-proven F2–F3 MASLD patients. A simple strategy combining FIB-4, metabolic risk factors (diabetes/overweight), and liver stiffness measurement may more accurately identify patients who are likely to benefit from treatment.

GLP-1RAs Linked to Lower Obesity-Related Cancer Risk : Ann Oncol | June 2026

Introduction: Obesity is a major risk factor for several malignancies, including colorectal, pancreatic, liver, endometrial, and other obesity-associated cancers (OACs). With the growing global burden of obesity, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have rapidly emerged as effective weight-loss therapies, even among individuals without diabetes. Beyond their metabolic benefits, increasing attention has focused on whether these agents may also influence cancer risk. Problem Statement: Previous studies have suggested a potential association between GLP-1RA use and reduced cancer incidence; however, most analyses included patients with diabetes, making it difficult to separate the effects of weight reduction from those of improved glycemic control. The impact of GLP-1RAs on cancer risk specifically in obese individuals without diabetes has remained largely unknown. Summary: In this large real-world study involving obese, nondiabetic adults, GLP-1RA therapy was associated with a substantially lower incidence of obesity-associated cancers compared with standard lifestyle interventions alone. The analysis evaluated a broad spectrum of obesity-related malignancies and demonstrated a consistent reduction in cancer occurrence among patients receiving GLP-1RAs during short-term follow-up. Importantly, the findings persisted across multiple sensitivity analyses and were observed in most patient subgroups, including different sexes, body mass index categories, and treatment agents such as semaglutide and tirzepatide. These results suggest that the benefits of GLP-1RAs may extend beyond weight loss and metabolic improvement, potentially influencing biological pathways involved in carcinogenesis. The study is particularly important because it isolates the association between GLP-1RA exposure and cancer risk in patients without diabetes, reducing a major source of confounding present in previous investigations. While the observational design and relatively short follow-up preclude conclusions regarding causality, the findings provide compelling evidence supporting further prospective evaluation. As GLP-1RAs become increasingly integrated into obesity management, their potential role in reducing obesity-related cancer burden may represent an important additional clinical benefit with significant implications for preventive oncology.

AI Fibrosis Mapping Redefines Risk in MetALD and ALD : Gastroenterology | June 2026

Introduction: Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol-Associated Liver Disease, and the recently recognized MetALD phenotype represent a rapidly expanding spectrum of chronic liver disease with overlapping metabolic and alcohol-related injury. Although steatotic liver disease (SLD) classifications have evolved, real-world outcome data comparing biopsy-proven subtypes remain limited, particularly regarding fibrosis biology and long-term prognosis. Problem Statement: Current fibrosis staging systems may not adequately capture biologic differences between MASLD, MetALD, and ALD. Whether these subtypes differ in clinical outcomes and fibrosis architecture despite similar conventional fibrosis stages remains uncertain. Improved phenotypic characterization is essential for precision risk stratification and individualized disease management. Summary: This multicenter prospective cohort study evaluated 2551 individuals with biopsy-proven steatotic liver disease or non-SLD controls between 2010 and 2023 to compare clinical outcomes across SLD subtypes. The investigators assessed risks of all-cause mortality, liver-related events, cardiovascular disease, and extrahepatic malignancies using competing-risk models. Additionally, artificial intelligence–based quantitative fibrosis analysis using second harmonic generation imaging was performed on liver biopsies from MASLD, MetALD, and ALD patients to characterize zone-specific collagen distribution patterns. During a median follow-up of nearly 44 months, both MetALD and ALD demonstrated markedly worse outcomes compared with non-SLD controls. MetALD was associated with a threefold increase in all-cause mortality risk and a sixfold increase in liver-related events, while ALD showed even greater risk amplification with substantially higher mortality and hepatic complication rates. Importantly, among patients with advanced fibrosis, ALD carried significantly worse outcomes than MASLD despite similar histologic fibrosis stages, highlighting important biological differences not captured by traditional staging systems. A major strength of the study was the incorporation of AI-driven fibrosis quantification. The imaging analysis demonstrated that MetALD and ALD had significantly greater collagen deposition within periportal and zone 2 regions compared with MASLD, despite comparable conventional fibrosis grades. These findings suggest that alcohol-associated injury may drive distinct fibrotic remodeling pathways with different prognostic implications. The study is highly relevant because it provides prospective biopsy-based evidence supporting the concept that MetALD behaves more aggressively than isolated MASLD and shares fibrosis characteristics closer to ALD. This has major implications for clinical practice because MetALD patients may currently be under-recognized despite carrying substantially elevated hepatic risk. The findings also reinforce the emerging role of AI-assisted pathology in liver disease. Traditional fibrosis staging offers semiquantitative assessment, whereas AI-based collagen mapping may provide more precise characterization of fibrosis architecture, disease biology, and prognostic heterogeneity. Clinically, the data support more intensive surveillance and risk stratification strategies for patients with MetALD and ALD, particularly those with advanced fibrosis. The study additionally highlights the importance of systematically assessing alcohol intake even in patients meeting metabolic dysfunction criteria, as coexistence of alcohol-related injury substantially alters prognosis. From a translational perspective, the identification of subtype-specific fibrosis patterns may facilitate development of targeted antifibrotic therapies and more individualized treatment algorithms. Overall, this study demonstrates that MetALD and ALD confer significantly higher mortality and liver-related complication risks than MASLD, while AI-based fibrosis mapping reveals distinct collagen distribution signatures that may redefine future precision hepatology approaches.

Breathomics Redefines Functional Liver Assessment : Clin Liver Dis | May 2026

Introduction Chronic Liver Disease continues to rise globally, driven predominantly by Metabolic Dysfunction-Associated Steatotic Liver Disease and alcohol-associated liver disease. Accurate evaluation of fibrosis severity and hepatic functional reserve remains fundamental for prognostication, transplant assessment and therapeutic decision-making. Problem Statement Current diagnostic tools, including liver biopsy and serum-based fibrosis scores, primarily provide static structural information and incompletely capture real-time hepatic metabolic function. There remains an unmet need for dynamic, non-invasive methods capable of simultaneously assessing hepatocyte function, fibrosis burden and metabolic reserve. Summary This narrative review highlights the evolving role of breath-based diagnostics as a physiologically grounded approach for functional liver assessment. Unlike conventional fibrosis tools that estimate structural injury indirectly, breath testing evaluates active hepatic metabolic capacity in real time. The review focuses primarily on isotope-based breath tests using 13C-labelled substrates. Following hepatic metabolism, these substrates generate measurable 13CO2 in exhaled breath, providing dynamic information regarding enzymatic activity, mitochondrial function, hepatic perfusion and viable hepatocyte mass. Importantly, breath-test kinetics also reflect the functional consequences of fibrosis progression rather than merely quantifying scar burden. This creates a clinically relevant distinction between structural fibrosis assessment and true hepatic reserve evaluation. The article further discusses volatile organic compound (VOC) analysis, an emerging “breathomics” strategy capable of identifying endogenous metabolic signatures associated with oxidative stress, inflammation and fibrogenesis. VOC profiling may eventually permit non-invasive molecular phenotyping of liver disease. A major focus of the review is the development of the Liver Isoform Breath Assessment platform. LIBRA integrates multiple 13C-labelled substrates simultaneously to interrogate several hepatic metabolic pathways within a single assessment, thereby generating a composite measure of dynamic liver function. Preliminary evidence suggests potential utility of LIBRA in fibrosis risk stratification, prediction of hepatic decompensation and transplant evaluation. By integrating multiple metabolic domains, LIBRA may provide a more comprehensive representation of hepatic reserve than conventional single-marker approaches. The review also positions breath diagnostics within the broader movement toward precision hepatology. Functional metabolic phenotyping may eventually help distinguish biologically heterogeneous patient subgroups within MASLD and cirrhosis populations. Clinically, breath testing offers several practical advantages. The technique is non-invasive, repeatable, radiation-free and potentially suitable for serial monitoring. Dynamic assessment may be particularly valuable in tracking disease progression, treatment response and peri-transplant physiology. The review additionally emphasizes the conceptual shift from static fibrosis staging toward integrated structure-function assessment. Patients with similar fibrosis stages frequently demonstrate markedly different metabolic reserve and clinical trajectories, highlighting limitations of purely structural evaluation. Importantly, the authors acknowledge several current limitations preventing routine clinical implementation. Standardization of testing protocols, validation across etiologies, establishment of diagnostic thresholds and demonstration of cost-effectiveness remain necessary before widespread adoption. Technical variability, substrate selection, analytical platform harmonization and reproducibility across centers also require further refinement. Large prospective studies will be essential to determine whether breathomics meaningfully improves clinical outcomes beyond existing fibrosis algorithms. Nevertheless, the review underscores the growing translational importance of non-invasive functional hepatology diagnostics. As MASLD prevalence increases globally, scalable tools capable of identifying patients at highest risk of decompensation and progression will become increasingly valuable. Overall, this review positions breath-based diagnostics and multi-substrate platforms such as LIBRA as promising next-generation tools that integrate hepatic structure, metabolism and functional reserve, potentially reshaping future non-invasive assessment strategies in chronic liver disease.

Histidine–ImP Axis Links Gut, Liver and Vascular Injury in MASLD : Biomed Pharmacother | May 2026

Introduction Metabolic Dysfunction-Associated Steatotic Liver Disease is increasingly recognized as a systemic disorder extending beyond hepatic steatosis and fibrosis. Cardiovascular disease remains the leading cause of mortality in MASLD, yet cardiovascular risk varies markedly among patients and is often poorly explained by liver disease severity or traditional metabolic risk factors alone. This discrepancy has intensified interest in microbiota-driven metabolic pathways linking the gut, liver and vascular system. Problem Statement Current models of MASLD inadequately explain why some patients develop disproportionate vascular and cardiometabolic complications despite similar hepatic disease burden. Novel mechanistic frameworks integrating microbial metabolism, host signaling and vascular inflammation are needed to better define biologic heterogeneity within MASLD. Summary This hypothesis-generating review proposes a novel gut–liver–vascular axis centered on microbial histidine metabolism and production of Imidazole Propionate (ImP). The authors suggest that altered microbial conversion of dietary L-histidine through the bacterial urdA pathway may represent a key mechanistic driver of both hepatic metabolic dysfunction and vascular inflammation in MASLD. The proposed model centers on a dual pathogenic mechanism. First, enhanced microbial histidine metabolism reduces bioavailable histidine, potentially impairing protective signaling pathways mediated through TAAR1. Histidine depletion may therefore weaken anti-inflammatory, metabolic and vascular homeostatic responses. Simultaneously, excessive production and systemic accumulation of ImP exerts direct deleterious metabolic effects. Experimental evidence reviewed in the article indicates that ImP interferes with insulin signaling within hepatocytes, thereby promoting hepatic steatosis and metabolic dysfunction. Beyond the liver, ImP also appears to activate proinflammatory and proatherogenic signaling cascades within endothelial tissue, suggesting a direct mechanistic bridge between intestinal microbial metabolism and cardiovascular injury. The review additionally highlights the bacterial urdA enzyme pathway as a potential functional biomarker of pathogenic microbiota activity. The authors introduce the concept of an “ImP-positive/urdA-high” microbial biotype, which could represent a clinically important MASLD endophenotype characterized by persistent cardiometabolic and vascular risk despite otherwise similar hepatic disease severity. This framework is especially important because it shifts focus from static taxonomic microbiome analysis toward functional microbial metabolism. Rather than simply identifying bacterial species abundance, the proposed model emphasizes metabolically active microbial pathways capable of directly modulating host cardiometabolic physiology. The implications for precision medicine are substantial. Therapeutic strategies could theoretically target multiple levels of the histidine–ImP axis, including dietary histidine modulation, suppression of microbial urdA activity, inhibition of ImP production or blockade of downstream ImP-mediated inflammatory signaling. Such approaches may help identify and treat MASLD patients with residual cardiovascular risk not captured by conventional metabolic profiling. Importantly, the review positions MASLD as a multidimensional gut-driven systemic disease rather than an isolated hepatic disorder. The proposed histidine–ImP pathway integrates microbiota metabolism, hepatic insulin resistance and vascular inflammation into a unified mechanistic model potentially explaining interpatient heterogeneity in disease expression and cardiovascular outcomes. Overall, this integrative review introduces the histidine–imidazole propionate axis as a compelling new conceptual framework for understanding gut–liver–vascular crosstalk in MASLD. The model provides a strong rationale for future microbiota-guided precision stratification and targeted metabolic interventions aimed at both hepatic and cardiovascular complications of steatotic liver disease.

Diet Quality Shapes MASLD Fibrosis Progression : Hepatol Commun | May 2026

Introduction Metabolic Dysfunction-Associated Steatotic Liver Disease is increasingly recognized as a major driver of progressive liver fibrosis, cirrhosis and liver-related mortality worldwide. Although obesity, insulin resistance and diabetes are well-established contributors, growing evidence suggests that specific dietary patterns independently influence hepatic inflammation and fibrogenesis. However, large-scale human data evaluating how individual foods and nutrient profiles affect MASLD progression have remained limited. Problem Statement While experimental models demonstrate that diet composition modulates hepatic fibrosis and metabolic injury, the specific dietary factors associated with fibrosis progression in real-world MASLD populations are not well defined. Identifying protective versus harmful nutritional patterns may help refine lifestyle interventions beyond simple caloric restriction. Summary This large Veterans Health Administration Million Veteran Program study evaluated more than 84,000 individuals with MASLD who completed detailed dietary and lifestyle assessments, including semiquantitative food frequency questionnaires. Investigators examined associations between dietary intake patterns, fibrosis progression and incident cirrhosis using longitudinal Fibrosis-4 trajectories and validated multivariable modeling approaches. Several dietary components were consistently associated with reduced fibrosis progression. Protective dietary patterns included frequent consumption of coffee, tea, legumes, nuts, vegetables such as broccoli and spinach, dairy products, white meat, rice/pasta and modest alcohol intake. Nutrients linked with favorable outcomes included caffeine, nitrate/vitamin K, betaine, amino acids and beta carotene. These findings support growing evidence that plant-rich, minimally processed diets with anti-inflammatory and antioxidant properties may mitigate hepatic fibrogenesis. In contrast, refined and processed carbohydrate-rich dietary patterns were strongly associated with accelerated fibrosis progression. Higher intake of white bread, cookies, breakfast cereals and non-heme iron–rich processed foods correlated with worsening fibrosis trajectories. Certain nutrient profiles, including excess refined carbohydrates and high-fructose processed foods, were similarly linked to adverse liver outcomes. The findings reinforce mechanistic data implicating hyperinsulinemia, oxidative stress, lipotoxicity and chronic low-grade inflammation in MASLD progression. Importantly, the study moves beyond generalized dietary recommendations by identifying specific food groups and nutrient signatures associated with either protection or progression. Coffee and caffeine again demonstrated strong hepatoprotective associations, consistent with prior studies showing antifibrotic, antioxidant and metabolic benefits. Similarly, nitrate- and vitamin K–rich vegetables may influence hepatic inflammation and endothelial function through modulation of nitric oxide signaling and oxidative pathways. The study also highlights that dietary quality may influence MASLD natural history independently of traditional metabolic risk factors. Even after adjustment for diabetes, obesity, alcohol use and baseline fibrosis severity, several dietary associations remained significant, suggesting direct biologic effects of nutritional composition on hepatic fibrogenesis. Overall, this large longitudinal cohort provides compelling real-world evidence that diet composition substantially influences fibrosis progression in MASLD. The findings support prioritization of plant-forward, minimally processed dietary patterns rich in vegetables, legumes, nuts and caffeine-containing beverages while limiting refined carbohydrates and ultra-processed foods as part of long-term MASLD management strategies.

Updated EASO Framework for Obesity Pharmacotherapy : Nat Med | May 2026

Introduction Obesity is increasingly recognized as a chronic, relapsing, multisystem disease requiring long-term, complication-oriented management rather than a purely weight-centric approach. The rapid expansion of anti-obesity pharmacotherapy, particularly incretin-based therapies and emerging combination agents, has substantially altered the therapeutic landscape. This 2026 update from the European Association for the Study of Obesity refines the European framework for obesity treatment by integrating new evidence regarding weight reduction, cardiometabolic outcomes and obesity-associated liver disease. Problem Statement Traditional obesity management algorithms relied heavily on body mass index thresholds and often underestimated the heterogeneity of obesity-related complications. The emergence of highly effective pharmacologic therapies has created uncertainty regarding optimal patient selection, treatment sequencing, duration of therapy and integration with metabolic, cardiovascular and hepatic risk stratification. In addition, obesity-related complications such as Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes increasingly require coordinated multidisciplinary treatment approaches. Summary This updated EASO framework emphasizes a complication-centric model of obesity care that prioritizes improvement in obesity-related disease burden rather than weight loss alone. The document highlights obesity as a biologically regulated chronic disease involving neuroendocrine, metabolic, inflammatory and behavioral pathways, thereby supporting earlier and more individualized pharmacologic intervention. The updated algorithm incorporates recent evidence from incretin-based therapies, particularly GLP-1 receptor agonists and dual incretin agonists, which now achieve weight reductions previously attainable mainly through bariatric surgery. The framework strongly advocates comprehensive baseline assessment including adiposity distribution, cardiometabolic risk, liver disease, sleep disorders, musculoskeletal disease and psychological health. Pharmacologic therapy is recommended not only according to BMI but also according to obesity-related complications and disease severity. Patients with established cardiovascular disease, MASLD/MASH, obstructive sleep apnea or diabetes are prioritized for early pharmacotherapy escalation because these populations derive substantial metabolic and organ-specific benefits beyond weight reduction alone. A major update in the 2026 guidance is the integration of emerging liver disease evidence. The framework recognizes the growing role of obesity pharmacotherapy in improving hepatic steatosis, metabolic dysfunction-associated steatohepatitis and fibrosis risk. GLP-1–based therapies are increasingly positioned as important therapeutic options for patients with obesity-associated liver disease, particularly when accompanied by diabetes or cardiometabolic dysfunction. The document also acknowledges the evolving role of combination therapies and future precision-based obesity medicine targeting specific biological phenotypes. Importantly, EASO emphasizes that pharmacotherapy should be integrated with structured lifestyle intervention rather than viewed as a replacement for behavioral treatment. Nutritional optimization, physical activity, sleep regulation and psychological support remain foundational. The framework also highlights the importance of preserving lean muscle mass during substantial pharmacologically induced weight loss through adequate protein intake and resistance exercise. The update further addresses the chronicity of obesity treatment, recognizing that discontinuation of therapy commonly results in weight regain and recurrence of metabolic complications. Long-term maintenance therapy is therefore increasingly viewed analogously to treatment strategies for hypertension or diabetes. Overall, the 2026 EASO framework reflects a major shift toward personalized, complication-driven obesity care integrating metabolic, cardiovascular and hepatic outcomes into therapeutic decision-making.

Global Consensus for MASLD Risk Stratification and Therapy : Clin Gastroenterol Hepatol | May 2026

Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) have emerged as dominant causes of chronic liver disease worldwide, paralleling the epidemics of obesity and type 2 diabetes. Fibrosis stage remains the strongest determinant of liver-related and overall mortality, shifting modern management toward fibrosis-centered care. With recent approval of resmetirom and semaglutide for noncirrhotic MASH with F2–F3 fibrosis, there is a growing need for standardized, noninvasive, globally applicable treatment algorithms. Problem Statement Clinical practice remains heterogeneous regarding the use of noninvasive tests (NITs), thresholds for treatment initiation and definitions of therapeutic response. Existing guidance varies across regions, while advanced imaging modalities remain inaccessible in many routine practice settings. Furthermore, the expanding therapeutic landscape requires practical strategies integrating fibrosis risk stratification, cardiometabolic profiling and longitudinal treatment monitoring. Summary This updated international Delphi consensus involved 40 multidisciplinary global experts who reviewed emerging evidence from 2025 onward to establish standardized recommendations for MASLD management. The panel strongly endorsed a sequential fibrosis-based approach using Fibrosis-4 Index (FIB-4) as the preferred first-line screening test, followed by vibration-controlled transient elastography (VCTE) or Enhanced Liver Fibrosis (ELF) testing for secondary risk stratification. For ELF testing, values below 9.2 were considered low risk for advanced fibrosis, whereas ELF ≥9.2 warranted hepatology referral and treatment consideration. Most experts favored higher treatment thresholds between 9.8 and 10.5 to improve specificity. ELF values >11.3 were considered suggestive of cirrhosis, making initiation of resmetirom or semaglutide inappropriate. For VCTE, liver stiffness <8 kPa indicated low risk, while values between 10–15 kPa represented the preferred therapeutic window for initiating pharmacologic therapy in noncirrhotic F2–F3 disease. Liver stiffness ≥20 kPa suggested cirrhosis and contraindicated treatment initiation with currently approved agents. The consensus emphasized individualized pharmacologic selection through shared decision-making. Semaglutide was generally preferred in treatment-naïve patients with coexisting obesity or type 2 diabetes because of its cardiometabolic benefits, whereas resmetirom was favored in patients already receiving GLP-1 receptor agonists. Upfront combination therapy with semaglutide and resmetirom was not recommended because of insufficient evidence, although sequential addition of the alternate agent for suboptimal responders was considered reasonable. Importantly, the document established objective response-monitoring criteria using NITs. A therapeutic response after approximately one year was defined as either a ≥30% reduction in liver stiffness on VCTE or a ≥0.5-point reduction in ELF score. Conversely, worsening fibrosis was defined as a >30% increase in liver stiffness or >0.5 increase in ELF, ideally confirmed using a second concordant NIT before treatment modification. The consensus also reinforced that lifestyle optimization remains foundational even in the era of pharmacologic therapy. Mediterranean-style dietary patterns, minimization of ultra-processed foods, structured aerobic and resistance exercise, and sustained weight reduction remain critical components of management. The authors particularly highlighted the risk of lean muscle loss during GLP-1RA-induced weight reduction and emphasized the importance of adequate protein intake and resistance training to prevent sarcopenic obesity. Overall, this consensus provides one of the first globally harmonized, fibrosis-centered, NIT-driven clinical algorithms integrating recently approved therapies into routine MASLD practice. The recommendations aim to standardize care pathways while maintaining flexibility for individualized cardiometabolic and hepatic risk assessment.

Wine, Food and Gut Health Multiomics : Adv Nutr | May 2026

Introduction Wine has historically been investigated for its cardioprotective effects, particularly in the context of the “French paradox,” but emerging evidence suggests that moderate wine consumption may exert broader physiological effects, especially on gut health and the microbiome. Wine contains a highly complex molecular matrix composed of polyphenols, organic acids, oligosaccharides, lipids, peptides and trace elements that interact dynamically with gut microbes and host metabolism. Advances in multiomics technologies are now enabling deeper characterization of these interactions and the biological “dark matter” of wine. Problem Statement Current understanding of wine-related health effects remains limited by reductionist approaches focused primarily on isolated compounds such as resveratrol or ethanol. The broader interactions between wine composition, co-consumed foods, gut microbiota and host physiology remain poorly defined. In particular, the molecular mechanisms underlying wine-food-gut interactions, interindividual metabolic variability and the role of microbial biotransformation require systematic investigation using integrated omics platforms. Summary This review proposes a comprehensive multiomics framework to investigate how wine components interact with food matrices and gut microbial ecosystems to influence local and systemic health. Moderate red wine consumption has been associated with increased gut microbial diversity and enrichment of potentially beneficial taxa including Bifidobacterium, Prevotella, Faecalibacterium prausnitzii and Roseburia, alongside reductions in lipopolysaccharide-producing bacteria. These microbiome shifts correlate with improvements in inflammatory and cardiometabolic markers, although causality remains unproven. Wine polyphenols undergo extensive microbial transformation in the colon, generating xenometabolites with bioactive potential that may contribute to intestinal barrier protection, antioxidant activity and metabolic regulation. The review highlights how metabolomics, glycomics, lipidomics, proteomics and ionomics are expanding understanding of wine’s molecular complexity. Metabolomic studies have identified hundreds of wine-associated metabolites linked to amino acid, lipid, carbohydrate and antioxidant pathways. Glycomic analyses reveal substantial diversity in wine oligosaccharides, which may possess prebiotic properties capable of modulating microbial communities and short-chain fatty acid production. Lipidomic and peptidomic approaches further suggest that wine-derived lipids and peptides could exert anti-inflammatory, antihypertensive and antimicrobial effects, although their physiological relevance remains insufficiently explored. Importantly, the authors emphasize that wine should not be studied in isolation from dietary context. Interactions between wine and Mediterranean dietary patterns, fats, proteins and carbohydrates substantially alter polyphenol bioavailability, microbial fermentation and metabolite generation. The review also underscores marked interindividual variability driven by genetics, microbiota composition and metabolic phenotypes, suggesting that personalized responses to wine consumption are likely substantial. Overall, the article advocates for integrated systems-level approaches that combine advanced multiomics, gut microbial profiling and human physiological phenotyping to better define how moderate wine consumption influences gut and systemic health.

MASLD in Older Adults Demands an Age-Specific Clinical Approach: Frontline Gastroenterology

Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) is now one of the most common chronic liver diseases worldwide, affecting nearly one in four adults. Although much of the clinical focus has centered on middle-aged populations, MASLD in older adults is increasingly relevant as global populations age and metabolic disease becomes more prevalent. In elderly individuals, MASLD presents unique diagnostic and therapeutic challenges that are often under-recognized in routine care. Problem Statement MASLD in adults aged 65 years and older is shaped by a distinct biological and clinical context marked by frailty, sarcopenia, multimorbidity and polypharmacy. Age-related changes in liver biology, including mitochondrial dysfunction, impaired autophagy and reduced regenerative capacity, may accelerate disease progression, while conventional diagnostic tools can overestimate fibrosis in this population. At the same time, therapeutic strategies developed in younger cohorts may not translate directly to older adults, who are frequently excluded from clinical trials and remain underrepresented in evidence-based treatment frameworks. Summary This review highlights ageing as a major modifier of MASLD biology, clinical presentation and management. In older adults, MASLD is influenced by age-related molecular changes such as telomere shortening, epigenetic drift and mitochondrial dysfunction, alongside shifts in body composition that favor visceral adiposity and sarcopenia. These factors increase vulnerability to advanced liver disease while complicating risk assessment and treatment. The authors emphasize that commonly used non-invasive fibrosis tools, particularly fibrosis-4, may overestimate fibrosis in elderly patients and should be interpreted with age-adjusted caution. Lifestyle modification remains the cornerstone of therapy, but interventions must be individualized to preserve muscle mass and avoid malnutrition. Emerging therapies, including resmetirom and glucagon-like peptide-1 receptor agonists, show promise, yet robust evidence in elderly populations remains limited. This review underscores the urgent need for age-adapted diagnostic pathways, inclusion of older adults in MASLD trials and a more geriatric-informed approach to steatotic liver disease care.

Nutrition in MASLD: Frontline Gastroenterology | April 2026

Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease worldwide and closely parallels the epidemics of obesity and type 2 diabetes. Lifestyle modification remains the first-line, evidence-based treatment, but in real practice there is often a major gap between guideline advice and what patients are actually able to follow. This review focuses on nutrition as the central modifiable factor in MASLD care, while also recognizing the importance of physical activity, sleep, culture, affordability, and food access. Problem Statement The major challenge in MASLD is not only knowing that diet matters, but translating broad recommendations into realistic, culturally sensitive, affordable, and sustainable nutrition advice for individual patients in busy clinical practice. Summary This review makes a strong case that nutrition should be at the centre of MASLD management. The main dietary message is to reduce ultra-processed foods, sugar-sweetened beverages, commercially produced fructose, saturated fats, and excess calories, while encouraging whole foods, vegetables, fruits, legumes, wholegrains, nuts, seeds, olive or rapeseed oil, and oily fish. The Mediterranean diet remains the most evidence-supported pattern because it improves liver fat and cardiometabolic health, sometimes even without significant weight loss. However, the authors rightly stress that the best diet is the one a patient can actually follow long term, so dietary advice must be personalized and culturally adapted. The review also explains the role of macronutrients and micronutrients. Fructose and saturated fat promote steatosis, while fibre, unsaturated fats, and adequate protein intake are protective. Micronutrients such as vitamin E, vitamin D, vitamin C, zinc, and polyphenols may influence liver health, although routine supplementation is not broadly recommended unless there is deficiency or a specific indication. Alcohol avoidance is emphasized, especially in more advanced disease. A particularly valuable part of this paper is its practical approach. It recognizes food insecurity, cost, and social context as real barriers. It gives adaptable Mediterranean-style advice for South and Southeast Asian, African, and lower-income populations, and even provides simple clinic checklists and sample menus. The overall message is clear: MASLD nutrition care should move from generic advice to compassionate, individualized, practical counselling that patients can sustain.

AI-Based Hepatic Fibre Phenotyping in MASLD: Hepatology | April 2026

Introduction Metabolically–dysfunction–associated steatotic liver disease (MASLD) is a complex and heterogeneous condition where fibrosis plays a central role in disease progression and hepatocellular carcinoma (HCC) risk. Traditional histological fibrosis staging, although widely used, often fails to capture the nuanced microstructural and molecular heterogeneity of liver tissue. With advances in artificial intelligence and multi-omics, there is an opportunity to redefine fibrosis beyond conventional staging and link structural changes with biological pathways. Problem Statement Current fibrosis assessment lacks precision in predicting disease progression, molecular alterations, and HCC risk in MASLD. There is a critical need for advanced phenotyping tools that can integrate tissue architecture with molecular signatures to improve risk stratification and therapeutic targeting. Summary This study introduces an AI-based platform (FibroNest) that identifies detailed hepatic fiber morphologies and classifies them into distinct phenotypic components (FibroPCs). These AI-derived patterns were superior to conventional fibrosis staging in capturing key molecular pathways, including IL-6 signaling and therapeutic responsiveness (e.g., resmetirom). Notably, a specific phenotype (FibroPC4) was strongly associated with future HCC risk and revealed a unique microenvironment driven by interactions between hepatic stellate cells and periportal endothelial cells. This work establishes AI-driven fibrosis phenotyping as a powerful tool for precision hepatology, enabling better prediction of disease progression and targeted therapy in MASLD.

Lean MASLD: Gut | April 2026

Introduction Metabolic dysfunction–associated steatotic liver disease (MASLD) has traditionally been linked with obesity and metabolic syndrome. However, an emerging subset—lean MASLD—is increasingly recognised, particularly in Asian populations. Despite having a normal body mass index, these patients exhibit metabolic dysfunction and hepatic steatosis. The long-term clinical implications of lean MASLD have remained unclear, with conflicting data regarding whether it represents a milder or equally aggressive phenotype compared to non-lean MASLD. Problem Statement Current clinical paradigms often underestimate lean MASLD due to the absence of obesity, leading to delayed diagnosis and risk stratification. There is a major gap in understanding whether lean MASLD carries similar, lower, or higher risks of liver-related events, mortality, and cardiovascular outcomes compared to non-lean MASLD. Summary This large multicohort prospective study involving over 180,000 patients across Western and Asian populations provides important clarity. Lean MASLD was associated with significantly higher risks of liver-related events, liver-related mortality, and overall mortality, highlighting a more aggressive hepatic phenotype despite normal BMI. Interestingly, lean MASLD showed similar risks of hepatocellular carcinoma and extrahepatic cancers, but lower cardiovascular disease risk compared to non-lean MASLD. These findings redefine lean MASLD as a high-risk but under-recognized clinical entity, emphasizing that absence of obesity does not imply a benign course. Clinicians must adopt a metabolic and liver-focused approach rather than BMI-based risk assessment, ensuring early detection, monitoring, and targeted management in this overlooked population.

Combination Therapies for MASH: JOH, April 2026

Introduction Metabolically–dysfunction–associated steatohepatitis (MASH) is a complex, multisystem disease driven by obesity, insulin resistance, lipotoxicity, inflammation, and fibrosis. Traditional single-drug therapies have shown limited success because they target only one pathway in a highly heterogeneous disease. As a result, there is a growing shift toward combination therapies that address multiple pathogenic mechanisms simultaneously, aiming for more effective disease modification and improved long-term outcomes. Problem Statement Monotherapy in MASH often leads to partial improvements in liver histology and metabolic parameters, with inconsistent effects on fibrosis regression and systemic disease burden. Given the multifactorial pathogenesis of MASH, there is a critical need for therapeutic strategies that can target both hepatic injury and systemic metabolic dysfunction while maintaining safety and tolerability. Summary This review highlights the emerging role of combination therapies as a paradigm shift in MASH management. Liver-directed combinations such as thyroid hormone receptor-β agonists with ACC inhibitors or PPAR agonists aim to directly improve steatosis and fibrosis. Systemic–hepatic combinations, including GLP-1 receptor agonists with FGF-21 analogues or THR-β agonists, address both metabolic dysfunction and liver disease. Novel dual or complementary drug pairings may also enhance efficacy while minimizing adverse effects. Overall, combination strategies offer a more comprehensive and personalized approach, with the potential to achieve meaningful fibrosis regression and

MASLD in Children and Adolescents: Journal of Hepatology | March 2026

Introduction Pediatric metabolic dysfunction-associated steatotic liver disease is increasingly recognized as one of the most important chronic liver diseases in children and adolescents, paralleling the global rise in obesity and metabolic dysfunction. This review highlights that MASLD in youth is not a benign condition, but a multisystem disease associated with early metabolic comorbidities, progression of liver fibrosis, and clinically meaningful liver-related outcomes in young adulthood. The article is particularly valuable because it brings together recent advances in epidemiology, genetics, natural history, non-invasive risk stratification, and therapeutic approaches, while also addressing the unique challenges of diagnosing and managing MASLD in children. Summary The review emphasizes that pediatric MASLD is rising worldwide, with the highest burden reported in the Middle East and North Africa, and that boys are affected more often than girls. The disease is strongly linked to obesity, insulin resistance, and early-life exposures such as maternal obesity, unhealthy diet, and metabolic programming in utero. The strongest genetic risk factor remains the PNPLA3 variant, although the overall genetic architecture appears broadly similar to that in adults. Importantly, pediatric MASLD is not simply a smaller version of adult disease, because children often display a portal-dominant pattern of injury, which may be linked to progression and advanced fibrosis. A major clinical message of this review is that pediatric MASLD should be approached as a multisystem disorder rather than an isolated liver condition. It is associated with increased risk of youth-onset type 2 diabetes, cardiovascular risk factors, renal impairment, and major adverse liver outcomes in early adulthood. Because liver biopsy is not practical for most children and existing adult fibrosis scores perform poorly in pediatrics, the article highlights the need for pediatric-specific non-invasive tests and proposes a pragmatic risk-stratified clinical framework. In terms of treatment, the authors strongly reinforce that multidisciplinary lifestyle intervention remains the foundation of care, while emerging signals from semaglutide, bariatric surgery, and intensive weight-loss programs suggest that meaningful liver improvement is possible. However, dedicated pediatric drug trials are urgently needed before pharmacologic treatment can be confidently recommended for liver-specific benefit.

Ketogenic Diets in MASLD: Journal of Hepatology | March 2026

Introduction Ketogenic diets, characterized by very low carbohydrate intake and increased fat consumption, have gained significant attention as a potential therapeutic strategy in metabolic dysfunction-associated steatotic liver disease. The rationale is biologically appealing: by reducing insulin levels and promoting lipolysis and hepatic β-oxidation, ketogenic diets may rapidly decrease intrahepatic fat and improve metabolic parameters. In an era where lifestyle interventions remain the cornerstone of MASLD management, understanding whether dietary composition—beyond simple caloric restriction—can meaningfully influence liver fat is of major clinical importance. Summary This article critically evaluates a recent mechanistic study suggesting superior reductions in intrahepatic triglyceride content and insulin resistance with ketogenic diets compared to non-ketogenic diets. While the findings support a “starvation-like” metabolic shift with increased fat oxidation and reduced insulin levels, the authors highlight key methodological limitations that challenge causal interpretation. The most important concern is the non-randomized crossover design, where all participants received the ketogenic diet first, followed by the non-ketogenic diet after a prolonged interval, introducing significant time-related confounding. Additionally, a substantial imbalance in protein intake between the two diets raises the possibility that observed metabolic changes may be driven by increased protein rather than ketosis itself. Finally, reliance on HOMA-IR as a surrogate for hepatic insulin sensitivity is questioned, as reductions in insulin and glucose during low-carbohydrate intake may reflect decreased metabolic demand rather than true improvement in insulin signaling. Overall, while ketogenic diets show potential in reducing liver fat, these findings underscore the need for rigorously designed trials before attributing benefits specifically to carbohydrate restriction.

GLP-1 RA in Gastroenterology: Digestive and Liver Disease | March 2026

Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now widely used for type 2 diabetes and obesity, two conditions frequently encountered in gastroenterology practice. Their effects extend far beyond glycemic control and weight loss, influencing the gut, pancreas, liver, biliary system, and peri-endoscopic care. Because these drugs are increasingly prescribed, gastroenterologists need practical, evidence-based guidance on how to use them safely in daily practice. Why This Position Paper Is Needed Although GLP-1RAs have shown major cardiometabolic benefits, clinicians continue to face important questions in gastroenterology: Are they safe in MASLD/MASH and cirrhosis? Do they increase the risk of GI or pancreatic cancers? Should they be routinely stopped before upper GI endoscopy? How should we manage GI side effects, pancreatitis concerns, and gallstone risk? This position paper from the Italian Society of Gastroenterology (SIGE) addresses these common clinical dilemmas and provides a practical framework for day-to-day management. Key Takeaways GLP-1RAs can be safely used in patients with diabetes or obesity and MASLD/MASH. They appear beneficial, especially in non-cirrhotic MASH, and semaglutide is highlighted as a disease-modifying option in selected patients with F2–F3 fibrosis. Semaglutide should be considered in adults with non-cirrhotic MASH and moderate-to-advanced fibrosis. It has shown meaningful benefit in MASH resolution and may improve fibrosis in selected patients. GLP-1RAs appear safe in cirrhosis. In patients with cirrhosis plus diabetes or obesity, these agents seem safe and may even reduce hepatic decompensation. A possible reduction in hepatocellular carcinoma risk is suggested. This is promising, but the evidence remains weak and largely observational. GLP-1RAs do not appear to increase the risk of major GI cancers. Available evidence does not support an increased risk of oesophagal, gastric, or colorectal cancer. Pancreatic cancer risk does not appear to increase. In fact, some studies suggest a possible reduction, but this remains uncertain. Routine discontinuation before upper GI endoscopy is not recommended. Current evidence does not support stopping GLP-1RAs routinely before gastroscopy. A liquid diet the day before upper GI endoscopy may be useful in selected cases. This is particularly relevant for: patients with nausea, vomiting, or dyspepsia longer or more complex endoscopic procedures Suspected retained gastric contents No extra bowel preparation is required before a colonoscopy. Standard colonoscopy preparation appears sufficient in most patients receiving GLP-1RAs. GLP-1RAs do not increase the risk of acute pancreatitis. This is an important reassurance for clinicians, although caution remains sensible in very high-risk patients. GLP-1RAs do increase the risk of cholelithiasis. This is one of the clearest safety signals and should be kept in mind, especially in rapid weight loss or pre-existing biliary risk. Mild GI adverse events are common, especially early after starting therapy. Nausea, vomiting, diarrhoea, constipation, and reflux symptoms are the most frequent issues. GI side effects are usually mild, transient, and dose-dependent. Most occur early and improve with time and gradual dose escalation. Severe GI complications are not increased. Serious events such as major obstruction, perforation, or severe complications are uncommon and not clearly more frequent than with placebo. GERD symptoms may worsen. Clinicians should ask about reflux symptoms, particularly in predisposed patients. Patient education is central to successful use. Practical advice includes: smaller meals avoiding high-fat meals good hydration slow dose titration temporary symptomatic treatment when needed Dose escalation matters. Slower titration can improve tolerability and reduce treatment discontinuation. Evidence quality remains limited for many recommendations. Much of the guidance is based on low or very low quality evidence, highlighting the need for better prospective studies. Conclusion This SIGE position paper supports the growing integration of GLP-1RAs into gastroenterology and hepatology practice. Overall, these drugs appear safe, clinically useful, and increasingly relevant, particularly in patients with obesity, diabetes, and MASLD/MASH. Routine discontinuation before upper endoscopy is generally unnecessary, pancreatitis risk is not increased, and cancer concerns are largely unsupported. The key practical issues are GI tolerability, reflux symptoms, and cholelithiasis, all of which can usually be managed with careful monitoring and thoughtful clinical judgment.

Resmetirom and MASLD Spectrum: Hepatology Communi — March 2026

Introduction Metabolically associated steatotic liver disease (MASLD) has become one of the most common causes of chronic liver disease worldwide, closely linked to the global epidemics of obesity and type 2 diabetes. The progressive form, metabolic dysfunction–associated steatohepatitis (MASH), can lead to fibrosis, cirrhosis, hepatocellular carcinoma, and liver transplantation. Until recently, treatment options were limited mainly to lifestyle modification. Resmetirom, a selective thyroid hormone receptor-β (THR-β) agonist, represents a new pharmacologic therapy targeting hepatic steatosis and inflammation and is now approved for MASH with F2–F3 fibrosis. Beyond histologic improvements, its effect on health-related quality of life (HRQL) across the MASLD spectrum remained uncertain. Summary This analysis from the MAESTRO-NAFLD-1 trial and its open-label extension evaluated HRQL outcomes in patients with early MASH and MASH cirrhosis treated with resmetirom. A total of 1143 patients with early MASH and 180 with MASH cirrhosis were included. HRQL was assessed using disease-specific instruments, including CLDQ-NAFLD and LDQoL. Patients with MASH cirrhosis had significantly poorer baseline quality-of-life scores compared with those with earlier disease. Treatment with resmetirom (80–100 mg) resulted in meaningful improvements in several HRQL domains, particularly worry, abdominal symptoms, and health distress, beginning by week 24 and sustained through week 52 and into year 2. Improvements were more pronounced in patients who achieved MRI-PDFF response, indicating a reduction in hepatic fat. Overall, the study demonstrates that resmetirom not only improves liver pathology but also enhances disease-specific quality of life in patients across the MASLD spectrum, including those with cirrhosis, supporting its broader clinical benefit beyond histologic endpoints.

Conventional Cardiovascular Risk Scores Underperform in Patients With MASLD: AMJ, March 2026

Metabolically–dysfunction–associated steatotic liver disease (MASLD) is strongly linked to cardiometabolic disorders, and cardiovascular disease (CVD) remains the leading cause of mortality in these patients. However, it is unclear whether commonly used cardiovascular risk prediction tools accurately estimate risk in this population. This study evaluated the performance of three widely used models—the Framingham Risk Score (FRS), Pooled Cohort Equation (PCE), and the American Heart Association PREVENT equation—in predicting cardiovascular events among patients with MASLD. Using data from the TARGET-NASH real-world cohort, the study included 1,090 US adults aged ≥30 years with MASLD. Researchers assessed the ability of these models to predict 5–10 year cardiovascular risk and compared predicted risk with actual observed cardiovascular events. The results showed that all commonly used tools performed poorly in this population. The FRS demonstrated weak discrimination (C-statistic 0.58), while the PREVENT model also showed limited predictive ability (C-statistic 0.60). In addition, both FRS and PCE showed significant calibration errors, meaning they overestimated risk in high-risk groups and underestimated risk in lower-risk groups. Importantly, the study also demonstrated that cardiovascular event rates increased progressively from MASLD to cirrhosis, suggesting that liver disease severity contributes independently to cardiovascular risk. Overall, these findings indicate that standard cardiovascular risk calculators are inadequate for patients with MASLD. Given the high cardiovascular mortality in this population, new risk assessment tools incorporating liver disease–specific factors are urgently needed to improve prediction, prevention, and clinical management.

Lean MASLD: Why Exercise Matters More Than Weight Loss: Gastroenterology | March 2026

Introduction – MASLD in Normal-Weight Individuals Metabolically dysregulated steatotic liver disease (MASLD) is commonly linked with obesity and metabolic syndrome. However, a significant subset of patients develop MASLD despite having a normal body mass index (BMI)—often referred to as lean or normal-weight MASLD. These individuals may still have metabolic abnormalities such as insulin resistance, visceral adiposity, or sedentary lifestyles. Current global MASLD guidelines recommend 3–5% weight reduction even in normal-weight individuals to reduce liver fat. However, emerging evidence suggests that focusing primarily on weight loss in this population may be misguided and clinically impractical. Why Weight Reduction May Not Help in Lean MASLD For patients already within a healthy weight range, further weight loss may provide limited metabolic benefit and can be difficult to achieve or sustain. More importantly, exercise exerts powerful liver-specific metabolic effects independent of body weight changes. Physical activity improves insulin sensitivity, enhances mitochondrial function, and increases hepatic fatty acid oxidation—mechanisms that directly reduce liver fat without requiring weight loss. Clinical studies show that structured aerobic or resistance exercise can reduce intrahepatic fat by 10–30%, even when body weight remains unchanged. Meta-analyses confirm that ≥150 minutes of moderate exercise weekly significantly improves hepatic steatosis independent of weight reduction. These findings suggest that in lean MASLD, lifestyle interventions should prioritise regular physical activity rather than weight-centric goals, reframing exercise as a direct therapeutic strategy rather than merely a tool for weight loss.

Dapagliflozin Reduces Liver Fat Independent of Weight Loss in T2D Obesity | Feb 2026 | DOI: 10.1002/oby.70134

Introduction In type 2 diabetes, hepatic steatosis is common and contributes to cardiometabolic risk. SGLT2 inhibitors improve weight and glycemia, but whether they reduce liver fat through weight loss alone or via a direct hepatic effect has remained uncertain. Summary This secondary analysis of a randomised, placebo-controlled trial studied 56 patients with type 2 diabetes assigned to placebo or dapagliflozin 10 mg for 12 months. Most participants (76%) had hepatic steatosis at baseline, and groups were comparable in metabolic risk and liver fat. Compared with placebo, dapagliflozin significantly reduced liver fat measured by MRI–proton density fat fraction (PDFF), alongside modest reductions in body weight and HbA1c. Crucially, mediation analysis showed that the reduction in liver fat was driven by a direct effect of dapagliflozin, while the indirect pathway via weight loss was not statistically significant. The findings suggest dapagliflozin can lower hepatic fat in T2D beyond its effects on weight and glycemic control, supporting further investigation of SGLT2 inhibitors as potential tools for managing metabolic dysfunction–associated steatotic liver disease.

Do Patients Want MASLD Screening? Hepatology | February 2026

Screening for metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly discussed, but concerns about anxiety, stigma, and overdiagnosis persist. This population-based study from Olmsted County evaluated how individuals perceive the benefits and harms of proactive MASLD screening. Among 461 screened participants (74% survey response rate), psychological impact was modest. Only 14% reported screening-related anxiety, and 14% were concerned about disclosing a potential diagnosis. Reassurance was substantial: 99% of participants without MASLD felt reassured about their liver health, 48% reported improved quality of life, and 25% adopted healthier lifestyle behaviours. Among 77 individuals diagnosed with MASLD, 52% experienced some anxiety; however, 95% believed early diagnosis was important to prevent cirrhosis, and 97% valued cardiovascular risk mitigation. Importantly, 79% reported the diagnosis motivated healthier habits, and 30% achieved >10% weight loss following screening. Overall, perceived benefits—including awareness, lifestyle change, and early prevention—outweighed psychological harms. Conclusion: Patient-centred MASLD screening appears acceptable and potentially empowering, supporting early detection strategies integrated with structured lifestyle interventions.

Do ACE Inhibitors and ARBs Improve Liver Outcomes in MASLD?- Hepatology Feb.26

Metabolic dysfunction–associated steatotic liver disease (MASLD) is tightly linked to cardiometabolic comorbidities, particularly hypertension. While blood pressure control is essential for cardiovascular risk reduction, whether antihypertensive drug choice influences liver-related outcomes has remained uncertain. This commentary reviews new evidence evaluating the potential role of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in MASLD. Using a large U.S. insurance database and a target trial emulation approach, Ng and colleagues compared MASLD patients newly started on ACEI/ARB with those started on calcium channel blockers. The analysis suggested that ACEI/ARB use was associated with a lower risk of major adverse liver outcomes, including hepatic decompensation, as well as fewer cardiovascular events. These findings align with preclinical data showing antifibrotic effects of renin–angiotensin system inhibition and support the concept that systemic metabolic therapies may influence liver disease progression. However, important limitations temper interpretation. As with all observational studies, residual confounding cannot be excluded, and the apparent cardiovascular advantage of ACEI/ARB over calcium channel blockers contrasts with results from randomized cardiovascular trials. Differences from prior Asian cohort studies—particularly regarding hepatocellular carcinoma risk—highlight how disease definitions, competing liver etiologies, and study design can influence results. In addition, the lack of granular fibrosis markers and treatment adherence data limits causal inference. In summary, ACEI/ARB therapy may offer dual cardiovascular and hepatic benefit in MASLD, but the evidence remains indirect. Until randomized trials are available, antihypertensive selection should prioritize established cardiovascular and renal indications, within a holistic strategy to manage metabolic risk in MASLD patients.

Hypertension Accelerates Liver Disease Progression in MASLD- AJG Feb.26

Introduction Metabolically–dysfunction–associated steatotic liver disease (MASLD) frequently coexists with hypertension, yet blood pressure has traditionally been viewed mainly through a cardiovascular lens. Whether hypertension directly influences liver disease progression and long-term hepatic outcomes has remained uncertain. This large, multicohort study addresses that gap by asking a simple but important question: Does hypertension independently worsen outcomes and fibrosis progression in MASLD? What the investigators did: The authors analysed three large, complementary cohorts: A population-based cohort to assess long-term clinical outcomes (death, cardiovascular events, liver-related events). A noninvasive elastography cohort to evaluate liver stiffness progression over time. A paired liver biopsy cohort to directly measure histologic fibrosis progression. By combining population data, noninvasive markers, and histology, the study provides a uniquely robust picture of disease evolution. Key findings clinicians should understand 1) Hypertension independently worsens long-term outcomes Patients with MASLD and hypertension experienced more adverse clinical events over time—not only cardiovascular events, but also liver-related complications and mortality. 2) Hypertension accelerates liver disease progression Across two independent measures of disease activity: Liver stiffness increased faster, and Fibrosis progressed more frequently in patients with hypertension compared with those without. 3) This is not just association—it’s consistent across methods The relationship between hypertension and MASLD progression was seen: in population-level data, with noninvasive fibrosis assessment, and on paired histologic evaluation. This consistency strongly supports a true biological link, not just confounding. Why this matters clinically Hypertension is modifiable Unlike many genetic or metabolic drivers, blood pressure is treatable—making it a practical intervention point. MASLD care must be multidisciplinary These findings emphasize that optimal MASLD management requires: hepatology, cardiology, and primary care alignment. Risk stratification should change Patients with MASLD and hypertension represent a higher-risk subgroup who may benefit from: closer fibrosis monitoring, earlier use of noninvasive tools (e.g., elastography), and more aggressive cardiometabolic risk control. Pathophysiologic perspective: Hypertension may contribute to liver injury through: endothelial dysfunction, altered hepatic microcirculation, systemic inflammation, and shared metabolic pathways with insulin resistance. These mechanisms provide biologic plausibility for the observed acceleration of fibrosis. Bottom-line takeaway from GastroAGI Hypertension is not just a cardiovascular comorbidity in MASLD—it is a key, modifiable driver of liver disease progression and adverse outcomes. Blood pressure control should be a core component of MASLD management. One-line GastroAGI takeaway In MASLD, controlling blood pressure may help protect the liver as much as the heart.

ANTICIPATE-NASH Beats Biopsy for Event Risk in MASLD- Gastroenterology Feb.26

Introduction In metabolic dysfunction-associated steatotic liver disease (MASLD), fibrosis stage on liver biopsy (F3 vs F4) remains the cornerstone for prognosis, surveillance, and clinical trial eligibility. However, real-world experience tells us that not all F3 patients behave the same, and not all F4 patients decompensate. This study challenges a long-standing paradigm: Is histology really the best way to stratify risk in advanced MASLD? The clinical problem Biopsy-based fibrosis staging has important limitations: It is invasive, costly, and prone to sampling variability It provides a static snapshot, not a dynamic risk estimate It performs poorly in predicting who will actually develop clinical events At the same time, portal hypertension—not fibrosis alone—drives outcomes in advanced MASLD. What the study did: Evaluated two large multicenter cohorts of patients with biopsy-proven F3–F4 MASLD Compared traditional histologic staging with the noninvasive ANTICIPATE-NASH models, which estimate risk of: clinically significant portal hypertension liver-related clinical events (decompensation, HCC, transplant, death) Tested whether biopsy added any meaningful prognostic value beyond the models Validated findings in an independent cohort from randomised clinical trials, using regulatory endpoints Key findings clinicians should understand 1) Noninvasive models clearly outperform histology ANTICIPATE-NASH stratified the risk of liver-related events far better than F3 vs F4 on biopsy. Histology alone showed limited ability to predict outcomes. 2) Biopsy adds no incremental value once the model is known When ANTICIPATE-NASH risk was included, the fibrosis stage did not improve prediction. In other words, the model already captured what truly matters for prognosis. 3) F3 and F4 patients overlap biologically Some F3 patients had high ANTICIPATE-NASH scores and developed clinical events Some F4 patients had low scores and remained stable This highlights why the fibrosis stage alone is an unreliable surrogate for risk. 4) Results hold up in clinical trial populations The superiority of ANTICIPATE-NASH over histology was confirmed using regulatory trial endpoints, strengthening the relevance for drug development. Why this matters for daily practice Risk stratification: Surveillance, intensity of follow-up, and counselling should move beyond biopsy labels. Clinical trials: ANTICIPATE-NASH can: enrich trials with patients likely to experience events Identify patients more likely to show cirrhosis regression, improving signal detection Future care models: This supports a shift from “what stage is the biopsy?” to “What is the patient’s actual risk?” Bottom-line takeaway: In advanced MASLD, noninvasive ANTICIPATE-NASH models predict real clinical outcomes far better than the liver biopsy fibrosis stage. Histology should no longer be considered the gold standard for risk stratification in this population. One-line GastroAGI takeaway In MASLD, prognosis is driven by risk, not biopsy stage.

Noninvasive markers and Prediction of treatment with Semaglutide (AP&T) - Jan,2026

As of my training cut-off in October 2023, I do not have access to specific information about a publication titled "Noninvasive markers and Prediction of treatment with Semaglutide (AP&T) - Jan, 2026." However, I can provide a detailed overview based on the context provided above about the use of non-invasive tests for assessing treatment response to semaglutide in MASH (Metabolic Associated Steatohepatitis). ### Overview of Non-Invasive Markers and Semaglutide in MASH 1. **Liver Biopsy Limitations**: - Liver biopsy is the gold standard for assessing liver conditions like MASH but is invasive, costly, and impractical for repeated monitoring. - This has driven the need to develop reliable non-invasive tools for monitoring treatment responses. 2. **Semaglutide in MASH**: - Semaglutide, a GLP-1 receptor agonist, is being explored as a treatment for MASH. - A phase 2b trial demonstrated that semaglutide could reduce liver damage and improve histological features of the disease. 3. **Non-Invasive Tests (NITs) as Potential Biomarkers**: - The study evaluated a broad panel of serum-based, imaging-based, and composite non-invasive tests to assess their utility in monitoring treatment response to semaglutide. - Examples of these tests include liver stiffness measurement, fibrosis-related biomarkers, and other composite scores. 4. **Key Findings from the Study**: - **Early Treatment Effects**: Reductions in non-invasive test scores were observed early during semaglutide treatment. - **Consistent Improvements**: All evaluated non-invasive tests showed improvement with semaglutide compared to placebo. - **Alignment with Histology**: Improvements in non-invasive tests were generally consistent with histological improvements, suggesting their potential as surrogate markers. - **Reduced Fibrosis Worsening**: Semaglutide-treated patients demonstrated less fibrosis progression compared to those on placebo. - **Baseline Risk Stratification**: Baseline levels of non-invasive tests were associated with future fibrosis progression or improvement, highlighting their prognostic value. 5. **Prognostic Utility**: - Fibrosis-related non-invasive tests, such as liver stiffness measurement, showed particular promise due to their existing clinical application and ability to predict disease progression. - Semaglutide treatment increased the likelihood of patients moving into lower clinical risk categories as assessed by non-invasive tests. 6. **Combined NIT Approach**: - The study suggested that using multiple non-invasive tests together might improve the robustness and reliability of treatment assessments. 7. **Challenges and Limitations**: - The findings were exploratory and not adjusted for multiple comparisons. - Larger, longer-term studies are required to validate the utility of non-invasive tests as regulatory biomarkers for treatment response in MASH. 8. **Clinical Implications**: - Non-invasive tests have the potential to replace liver biopsy for monitoring treatment response in MASH. - If validated in future studies, these tests could streamline clinical trials, reduce patient burden, and facilitate broader adoption of treatments like semaglutide. 9. **Future Directions**: - Further research is needed to confirm the findings in larger cohorts and over longer durations. - Regulatory approval of non-invasive tests as biomarkers for treatment response would be a significant step forward in MASH management. If you are referring to a specific study or publication from January 2026, I recommend consulting the original source or related journals such as *Alimentary Pharmacology & Therapeutics (AP&T)* for the most up-to-date and detailed information.

HCC Risk Prediction in Chronic HBV With Metabolic Dysfunction

Hepatocellular carcinoma (HCC) risk prediction in patients with chronic hepatitis B virus (HBV) infection who also have metabolic dysfunction is a complex but crucial aspect of clinical care. This population faces a compounded risk due to the interplay of chronic HBV infection and metabolic comorbidities, such as obesity, diabetes, hypertension, and dyslipidemia. Below is a detailed breakdown of the key factors, tools, and considerations for HCC risk prediction in this unique group: --- ### **1. Dual Disease Burden** Patients with chronic HBV and metabolic dysfunction represent a high-risk group due to the combined impact of viral and metabolic factors on liver health. This dual burden increases the likelihood of liver-related complications, including cirrhosis and HCC. Effective risk prediction and management are essential to mitigate these outcomes. --- ### **2. Importance of Metabolic Comorbidities** Metabolic dysfunction-associated conditions—such as overweight, diabetes, hypertension, and dyslipidemia—are significant contributors to adverse liver outcomes in chronic HBV. These conditions exacerbate liver inflammation, fibrosis progression, and overall disease severity, thereby influencing HCC risk. --- ### **3. Role of MASLD** Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), often coexists with chronic HBV. However, MASLD itself does not independently worsen HCC risk beyond the impact of metabolic dysfunction. The presence of steatosis (fatty liver) is not a decisive factor for HCC risk once metabolic dysfunction is accounted for. --- ### **4. Key Determinants of HCC Risk** Several factors play a critical role in predicting HCC risk in chronic HBV patients with metabolic dysfunction: - **Cirrhosis:** The presence of cirrhosis is the strongest clinical indicator of HCC risk. Patients with cirrhosis require closer monitoring, even if other risk factors are minimal. - **Age:** Increasing age is consistently associated with higher HCC risk in this population. Older patients are more likely to develop liver-related complications. - **Platelet Count:** Low platelet levels reflect advanced liver disease and are linked to a higher HCC risk. - **Albumin Levels:** Reduced albumin levels indicate impaired liver function and are associated with worse outcomes. - **Metabolic Factors:** Conditions like diabetes and obesity further amplify the risk. --- ### **5. Risk Prediction Tools: PAGE-B Score** The PAGE-B score is a validated and practical tool for predicting HCC risk in patients with chronic HBV, including those with metabolic dysfunction. It incorporates key variables such as age, gender, and platelet count, making it simple and accessible for clinical use. - **Consistency Across Metabolic Conditions:** The predictive performance of the PAGE-B score remains stable across various metabolic comorbidities, reinforcing its reliability in this complex population. - **Utility Beyond HCC:** The PAGE-B score also correlates with the risk of broader liver-related events, not just HCC, making it a versatile tool. - **Low-Risk Group Identification:** Patients with low PAGE-B scores and no cirrhosis are at minimal risk of HCC and may avoid intensive surveillance, improving resource efficiency. - **Residual Risk in Cirrhosis:** Even patients with low PAGE-B scores who have cirrhosis retain a meaningful risk of HCC and require ongoing monitoring. Other risk models are available, but the PAGE-B score is favored due to its simplicity and widespread applicability. --- ### **6. Personalized Surveillance Approach** HCC risk is not uniform across all patients with chronic HBV and metabolic dysfunction. A personalized approach to risk stratification and surveillance is essential: - **High-Risk Patients:** Individuals with cirrhosis, advanced age, low platelet counts, and low albumin levels require intensive monitoring and regular imaging for early HCC detection. - **Low-Risk Patients:** Those without cirrhosis and with low PAGE-B scores may benefit from less frequent surveillance, reducing unnecessary procedures and healthcare costs. --- ### **7. Implications of Antiviral Therapy** Antiviral therapy for chronic HBV does not directly increase HCC risk. Instead, associations between antiviral therapy and outcomes reflect the underlying severity of liver disease. Effective antiviral treatment remains a cornerstone of HBV management and can help reduce long-term liver complications. --- ### **8. Addressing Metabolic Dysfunction** Managing metabolic dysfunction is an important component of reducing HCC risk in this population. Interventions targeting weight loss, glycemic control, lipid management, and blood pressure regulation may mitigate liver-related risks and improve overall outcomes. --- ### **9. Clinical Practice Relevance** The integration of metabolic assessment with established HBV risk tools, such as the PAGE-B score, enables a more comprehensive approach to HCC risk prediction. This strategy allows clinicians to: - Identify high-risk patients who need intensive surveillance. - Avoid over-monitoring low-risk individuals, optimizing healthcare resources. - Address metabolic comorbidities to reduce long-term liver complications. --- ### **Conclusion** HCC risk prediction in chronic HBV patients with metabolic dysfunction requires a nuanced approach that considers both viral and metabolic factors. Tools like the PAGE-B score provide a reliable framework for stratifying risk and guiding surveillance strategies. By integrating metabolic management into HBV care, clinicians can further reduce the burden of liver-related complications and improve patient outcomes.

Phase III Trial of Norursodeoxycholic Acid in MASLD

The Phase III trial of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) was designed to evaluate the efficacy and safety of this promising therapeutic option in a broader patient population. MASLD is a highly prevalent chronic liver condition associated with obesity, insulin resistance, diabetes, and dyslipidaemia. It progresses from simple steatosis to more severe forms like steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma, while also increasing the risk of extrahepatic complications. Despite its growing global impact, MASLD often remains asymptomatic in its early stages, and no widely approved pharmacological treatments are available. Lifestyle modifications are the primary management strategy, but long-term adherence and effectiveness are often challenging. ### Key Highlights of the Phase III Trial: 1. **Objective**: The trial aimed to evaluate whether norursodeoxycholic acid, a modified bile acid with enhanced hepatic activity and antifibrotic mechanisms, could improve liver function and noninvasive markers of fibrosis in patients with MASLD. 2. **Background**: Ursodeoxycholic acid has previously shown biochemical improvements in MASLD patients but demonstrated limited histological efficacy. Norursodeoxycholic acid, on the other hand, has shown promise in preclinical and early clinical studies due to its ability to target hepatic inflammation and fibrosis, the key drivers of disease progression. Robust Phase III evidence was needed to confirm its therapeutic role. 3. **Design**: The trial was randomized, placebo-controlled, and involved patients diagnosed with early-stage MASLD. Participants were assigned to receive norursodeoxycholic acid or a placebo over a defined period, with regular assessments of liver function, fibrosis markers, and safety parameters. 4. **Results**: - **Efficacy**: Norursodeoxycholic acid demonstrated clinically meaningful improvements in liver function and noninvasive markers of fibrosis. These results suggest its potential to slow or halt the progression of MASLD. - **Safety and Tolerability**: The drug maintained a favorable safety profile, with minimal adverse effects reported during the trial. This reinforces its suitability for long-term use in MASLD patients. 5. **Conclusion**: The findings from this Phase III trial support norursodeoxycholic acid as a promising therapeutic option for early-stage MASLD. It addresses an important unmet need by targeting hepatic inflammation and fibrosis, which are critical drivers of disease progression. The drug's safety and efficacy make it a viable candidate for routine clinical practice, especially for patients who struggle with lifestyle modifications or lack effective pharmacological treatments. ### Implications: The results of this trial mark a significant step forward in the management of MASLD. Norursodeoxycholic acid could potentially fill the gap in pharmacological treatment options for this highly prevalent condition, offering hope to millions of patients worldwide. Further studies may explore its long-term benefits, impact on advanced stages of MASLD, and potential use in combination therapies.

FIB-4 as a Referral Index for Coronary Artery Calcification in MASLD

The Fibrosis-4 (FIB-4) index has emerged as a potentially valuable tool for assessing the risk of coronary artery calcification (CAC) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). This study highlights the utility of FIB-4 as a noninvasive marker that can stratify cardiovascular risk and guide clinical decision-making in MASLD patients. ### Key Findings: 1. **Association Between MASLD and CAC**: - Individuals with MASLD were found to have a higher prevalence of coronary artery calcification compared to those without MASLD. - This suggests that MASLD, which is characterized by steatotic liver disease and cardiometabolic risk factors, is closely linked to coronary atherosclerosis. 2. **Role of FIB-4 Index**: - The FIB-4 index, a simple calculation based on age, platelet count, AST (aspartate aminotransferase), and ALT (alanine aminotransferase), was used to estimate liver fibrosis severity. - Higher FIB-4 values were associated with more advanced coronary calcification, indicating a greater risk of coronary artery disease (CAD). - Conversely, lower FIB-4 values were effective in identifying individuals at low risk of severe CAC. 3. **Progressive Risk in MASLD**: - In MASLD patients, increasing liver fibrosis severity (reflected by higher FIB-4 values) corresponded with progressively higher coronary calcium levels. - This relationship underscores the interconnectedness of liver fibrosis and cardiometabolic burden in driving coronary atherosclerosis. ### Clinical Implications: - **Risk Stratification**: - FIB-4 can serve as a practical, noninvasive index to stratify cardiovascular risk in MASLD patients. Elevated FIB-4 values may identify individuals who require closer cardiovascular monitoring and intervention. - Patients with low FIB-4 scores may be considered at lower risk for severe CAC, potentially reducing the need for more invasive diagnostic procedures. - **Early Preventive Care**: - Routine use of the FIB-4 index in MASLD patients can guide early preventive measures to mitigate cardiovascular risk, including lifestyle modifications, pharmacological interventions, and closer monitoring for coronary artery disease. - **Integration in Clinical Practice**: - The FIB-4 index is inexpensive, widely accessible, and easy to calculate, making it a feasible tool for routine use in primary care and specialized settings. ### Conclusion: The study underscores the clinical utility of the FIB-4 index as a referral index for coronary artery calcification in MASLD patients. By identifying individuals at increased risk of coronary atherosclerosis, FIB-4 can help optimize cardiovascular risk stratification and facilitate early preventive care. This approach may ultimately improve long-term outcomes for patients with MASLD and associated cardiometabolic conditions.

Semaglutide for MASLD: AASLD Practice Guidance November 2025

As of my knowledge cutoff in October 2023, I cannot provide specific details about the AASLD Practice Guidance from November 2025 regarding semaglutide for MASLD (metabolic dysfunction-associated steatotic liver disease). However, based on the provided context and existing knowledge, I can offer a projected understanding of how semaglutide might fit into MASLD treatment according to evolving clinical guidance. ### Overview of Semaglutide in MASLD Management (Based on Context) 1. **FDA Approval for MASH (2025)**: - Semaglutide (Wegovy®) received accelerated FDA approval in August 2025 for treating metabolic dysfunction-associated steatohepatitis (MASH) with stage F2–F3 fibrosis based on the ESSENCE Phase 3 trial results. 2. **Efficacy in MASH**: - The ESSENCE trial demonstrated significant histologic improvements: - MASH resolution in 62.9% of patients. - Fibrosis reduction in 36.8% of patients compared to placebo. 3. **Noninvasive Diagnosis and Monitoring**: - The AASLD recommends noninvasive tests (NITs) such as VCTE (FibroScan), MRE, or ELF for fibrosis assessment, discouraging routine liver biopsies. - Recommended NIT ranges for identifying treatment candidates: - VCTE: 8–15 kPa. - MRE: 3.1–4.4 kPa. - ELF: 9.2–10.5. 4. **Exclusion of Cirrhosis**: - Patients with evidence of cirrhosis (e.g., VCTE > 20 kPa, MRE > 5 kPa, or ELF > 11.3) are not candidates for semaglutide as a sole treatment for MASH. 5. **Safety and Adverse Effects**: - Semaglutide has a favorable hepatic safety profile, with no liver enzyme-related discontinuations in the ESSENCE trial. - Common mild side effects include nausea, diarrhea, constipation, and vomiting. - Rare but serious risks include acute kidney injury, gallbladder disease, pancreatitis, thyroid C-cell tumors, and retinopathy progression. - Lean mass loss (~13% in trials) requires attention to exercise and protein intake. 6. **Lifestyle Modifications as Core Therapy**: - Dietary changes, weight management, and physical activity remain foundational in MASH therapy, even with semaglutide use. 7. **Cardiovascular and Renal Benefits**: - Semaglutide reduces major adverse cardiovascular events (MACE) in obese or diabetic patients and likely provides similar benefits for MASH patients. - The FLOW trial (2025) showed reduced risk of kidney failure and cardiovascular death in T2DM patients with chronic kidney disease. 8. **Indicators of Response and Non-Response**: - Positive response indicators: ALT reduction (>17 U/L or >20%), CAP > 30%, VCTE ≥ 30%, MRE ≥ 20%, or ELF > 0.5 from baseline. - Non-response: Worsening ALT or NIT values may suggest treatment futility, requiring reassessment or discontinuation. ### Projected AASLD Guidance (November 2025) While specific details of the November 2025 AASLD Practice Guidance are unavailable, it is reasonable to expect the following recommendations based on the context: 1. **Eligibility Criteria**: - Patients with MASLD (specifically MASH) and moderate to advanced fibrosis (F2–F3) may be considered for semaglutide therapy. - Noninvasive tests (NITs) should guide patient selection, avoiding liver biopsies unless absolutely necessary. 2. **Exclusion of Cirrhosis**: - Patients with cirrhosis should not receive semaglutide for MASH treatment alone, as its efficacy in advanced liver disease remains unproven. 3. **Safety and Monitoring**: - Routine liver function tests are not required unless clinically indicated. - Patients should be monitored for potential adverse effects, including gastrointestinal symptoms, lean mass loss, and rare complications like pancreatitis or retinopathy. 4. **Lifestyle Interventions**: - Lifestyle changes, including diet, exercise, and weight loss, remain the cornerstone of MASLD management and should accompany semaglutide therapy. 5. **Combination Therapy**: - The guidance may advise caution regarding concurrent use of semaglutide with other investigational agents like resmetirom, as formal studies on combination therapy are lacking. 6. **Long-Term Outcome Verification**: - The AASLD may emphasize the need for long-term outcome data from the ESSENCE trial (expected by 2028 or later) to confirm the durability of semaglutide's benefits in MASH. ### Conclusion Semaglutide represents a promising therapeutic option for MASH with F2–F3 fibrosis, supported by strong clinical trial evidence (ESSENCE). However, its use should align with AASLD recommendations, focusing on appropriate patient selection, safety monitoring, and integration with lifestyle modifications. For definitive details on the November 2025 AASLD Practice Guidance, consulting the official document or updates beyond October 2023 is essential.

M-ACCEL trial

The M-ACCEL trial is a phase IIa study that evaluated the investigational oral drug HU6 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This trial aimed to assess the drug's efficacy in reducing liver fat and its impact on body composition over a 26-week treatment period. HU6 was tested in three daily doses: 150 mg, 300 mg, and 450 mg, alongside a placebo group for comparison. The trial demonstrated that HU6 significantly reduced liver fat in patients with MASH. Patients receiving HU6 experienced reductions in liver fat content of 29.4%, 31.2%, and 27% for the 150 mg, 300 mg, and 450 mg doses, respectively, compared to only 6.7% in the placebo group—a statistically significant difference (P=0.005). More than half of the patients on HU6 achieved at least a 30% reduction in liver fat, far exceeding the 22% response rate in the placebo group. Importantly, these reductions occurred without loss of skeletal muscle mass, which is critical for managing weight-related liver diseases. Additionally, HU6 impacted body composition, with the 450-mg dose leading to significant fat loss (–2.4 kg) compared to placebo (–0.9 kg). Muscle mass remained stable across all HU6 groups. HU6 functions as a controlled metabolic accelerator, increasing mitochondrial energy usage, and offers a promising oral treatment option for MASH with mild side effects and good safety profiles.

The ELMWOOD- Phase II trial

The ELMWOOD Phase II trial is a clinical study evaluating the efficacy and safety of elafibranor (brand name Iqirvo) for the treatment of primary sclerosing cholangitis (PSC). PSC is a rare, chronic liver disease that causes inflammation, scarring, and narrowing of the bile ducts, which can eventually lead to liver failure. Currently, there are no approved treatments for PSC, making this an area of significant unmet medical need. ### Key Findings from the ELMWOOD Phase II Trial: 1. **Study Design**: - The trial included an open-label extension phase, where patients who initially received a placebo were switched to elafibranor at a 120 mg daily dose. Other participants either continued on their original treatment dose or had their dose increased. 2. **Efficacy Results**: - **Alkaline Phosphatase (ALP)**: - ALP is a key liver enzyme and biomarker linked to disease activity in PSC. - Patients who switched from placebo to elafibranor (120 mg daily) experienced rapid and sustained reductions in ALP levels: - A 36% reduction in ALP at week 4. - A 40% reduction in ALP at week 28. - Patients who had been on the 120 mg dose from the start of the trial achieved even greater reductions: - A 46% reduction in ALP at week 28. - Patients whose dose was increased from 80 mg to 120 mg showed a 35.6% reduction in ALP, indicating continued improvement with higher dosing. - **Other Liver Enzymes**: - Elafibranor also improved levels of other liver enzymes, including ALT, AST, GGT, and bilirubin, across all treatment groups. - **Pruritus (Itching)**: - Itching, one of the most debilitating symptoms of PSC, improved in all treatment cohorts. - **Fibrosis Assessments**: - Noninvasive measures of liver fibrosis showed stabilization or modest improvement, suggesting potential long-term benefits for liver health. 3. **Safety Profile**: - The safety findings were generally acceptable: - 52% of patients reported treatment-emergent side effects, most of which were mild. Common side effects included COVID-19, nausea, itching, and weight gain. - Serious adverse events occurred in 5% of participants, but none were attributed to elafibranor. - The safety data supports the continued development of elafibranor for PSC. 4. **Significance**: - The interim results indicate that elafibranor is a promising therapeutic candidate for PSC. It has demonstrated meaningful improvements in liver markers, symptoms like pruritus, and potentially slowed disease progression. This is particularly important given the lack of approved treatments for this rare and serious liver disease. ### Conclusion: The ELMWOOD Phase II trial highlights elafibranor's potential to address the significant unmet medical need in PSC. Its ability to improve liver enzyme levels, alleviate symptoms, and potentially impact long-term liver health makes it a promising therapy for further clinical development.

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist

**GLP-1 Receptor Agonist Overview** A GLP-1 receptor agonist is a type of medication that mimics the action of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 is a naturally occurring hormone that helps regulate blood sugar levels, appetite, and digestion. These drugs are widely used in the treatment of type 2 diabetes and obesity. They work by increasing insulin secretion, slowing gastric emptying, and reducing appetite, which leads to weight loss and improved blood sugar control. **Why an Oral GLP-1 Agonist is Needed** Traditional GLP-1 receptor agonists, like semaglutide, are administered via injection, which can be inconvenient or undesirable for some patients. An oral GLP-1 agonist, such as Orforglipron, offers a convenient, non-invasive alternative, potentially improving patient adherence and accessibility for long-term obesity and metabolic disorder management. **What is Orforglipron?** Orforglipron is a novel, nonpeptide, small-molecule GLP-1 receptor agonist specifically designed for oral administration. It represents a significant advancement in obesity treatment by providing an effective, convenient alternative to injectable GLP-1 therapies. Beyond weight loss, Orforglipron also offers cardiometabolic benefits, such as improved blood pressure, cholesterol, and triglyceride levels. **Study Summary (100 Words)** A 72-week phase 3 trial evaluated Orforglipron, an oral GLP-1 receptor agonist, in 3,127 adults with obesity (without diabetes). Participants received 6 mg, 12 mg, or 36 mg daily doses or placebo, alongside lifestyle modifications. Orforglipron demonstrated dose-dependent weight loss (up to −11.2% with 36 mg vs. −2.1% placebo), with 54.6% of the 36 mg group losing ≥10% of body weight. Cardiometabolic markers, including waist circumference, blood pressure, and lipids, improved significantly. Adverse effects, mainly gastrointestinal, were mild to moderate. Orforglipron’s efficacy and safety profile matched injectable GLP-1 therapies, making it a promising oral alternative for long-term obesity management.

Tobacco and MASLD

Tobacco use, both active and passive, significantly influences the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Active smoking increases MASLD risk through mechanisms such as oxidative stress, inflammation, and metabolic disruption. Tobacco-induced oxidative stress damages liver cells (hepatocytes), promotes insulin resistance, and facilitates fat deposition in the liver, which are hallmark features of MASLD. Smoking also elevates systemic inflammatory markers like C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6), exacerbating hepatic inflammation and fibrosis. Additionally, smoking disrupts the gut–liver axis by altering gut microbiota, increasing intestinal permeability, and allowing endotoxins to enter the liver, further driving inflammation. The risk of MASLD is dose-dependent, with smokers who consume ≥20 pack-years of tobacco experiencing a 32% higher risk, highlighting the cumulative effect of tobacco exposure. Passive smoking, or secondhand smoke exposure, also contributes to MASLD, increasing risk by 13%. This underscores the harmful effects of indirect tobacco exposure, which impacts liver function even in non-smokers. Metabolic factors amplify the impact of smoking on MASLD. Individuals with obesity (BMI ≥24), hypertension, or high triglycerides face significantly higher risk due to the synergistic effects of smoking and metabolic dysfunction. Smoking impairs insulin signaling and lipid metabolism, worsening metabolic and hepatic health. Older adults and those with cardiometabolic conditions are particularly vulnerable. Importantly, smoking cessation has a protective effect. Quitting for more than 10 years reduces MASLD risk close to that of non-smokers, though damage persists for those who quit less than 10 years ago. Public health initiatives targeting smoking cessation and secondhand smoke regulation are crucial for MASLD prevention.

GLP-1 Receptor Agonists and Gastrointestinal Adverse Events

GLP-1 receptor agonists (GLP-1RAs) are medications commonly used to treat type 2 diabetes, obesity, and metabolic liver diseases. A meta-analysis of 55 randomized trials involving over 106,000 participants examined their gastrointestinal safety. The study found that GLP-1RAs are linked to a 46% higher risk of cholelithiasis (gallstones), which equals about 2 extra cases per 1000 people treated. Additionally, they were associated with a twofold increased risk of gastroesophageal reflux disease (GERD), leading to 4 extra cases per 1000 patients. However, no significant increase was observed in other gastrointestinal risks like pancreatitis, cholangitis, or intestinal obstruction. The risks of gallstones and GERD were more pronounced in patients with obesity, liver conditions like MASLD/MASH, those using GLP-1RAs for weight loss, or taking higher doses. These effects may result from rapid weight loss and reduced gallbladder motility (for gallstones) or delayed gastric emptying (for GERD). Despite these risks, GLP-1RAs are considered safe overall, as severe gastrointestinal complications were not significantly elevated. Clinicians should monitor gallbladder and reflux symptoms in patients on GLP-1RAs, especially those on weight-loss formulations or higher doses. The benefits of these drugs often outweigh their modest risks, making them a valuable therapeutic option.

Autoantibodies and outcome of MASLD

Autoantibodies, specifically ANA (antinuclear antibodies) and ASMA (anti-smooth muscle antibodies), are immune system proteins that mistakenly target the body’s own tissues. These autoantibodies were studied in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) to understand their impact on disease progression and outcomes. The research found that autoantibodies are relatively common in MASLD, with 17% of patients testing positive for ANA, 25% for ASMA, and 8% positive for both. The presence of these autoantibodies significantly worsens the prognosis of MASLD. Patients who tested positive for ANA or ASMA had a nearly fourfold higher risk of liver decompensation and over twofold higher risk of death compared to those without autoantibodies. Autoantibody positivity independently predicted progression to advanced liver disease, even after accounting for other risk factors like obesity and diabetes. The study suggests that these autoantibodies act as markers of systemic or liver inflammation rather than directly causing damage. Increased inflammation linked to autoantibodies reflects heightened immune activation, which contributes to disease severity. MASLD patients with autoantibodies often present with advanced fibrosis (F3–F4) and are at higher risk for complications like compensated advanced chronic liver disease (cACLD), hepatocellular carcinoma (HCC), and death. Screening for ANA and ASMA can help identify high-risk patients for closer monitoring and tailored treatment.

T2DM, GLP-1 Receptor Agonists and Liver Protection

GLP-1 receptor agonists (GLP-1RAs) have emerged as a promising therapeutic option for type 2 diabetes mellitus (T2DM) due to their multifaceted benefits, including significant liver protection. Here is a detailed explanation of their role in liver health and protection: ### 1. **Significant Hepatocellular Carcinoma (HCC) Risk Reduction** GLP-1RAs have been shown to markedly lower the risk of hepatocellular carcinoma (HCC), a primary form of liver cancer. Compared to other diabetes medications such as insulin and sulfonylureas: - **GLP-1RAs vs. Insulin**: GLP-1RAs reduced HCC risk with a hazard ratio (HR) of 0.20, indicating an 80% lower risk compared to insulin use. - **GLP-1RAs vs. Sulfonylureas**: The risk reduction was also significant (HR 0.78), showcasing their superior protective effects. ### 2. **Broad Liver-Protective Effects** GLP-1RAs consistently demonstrated hepatic protection across six different comparator drug classes. These agents reduce the risk of hepatic decompensation, a severe consequence of liver disease, suggesting their broad and reliable liver-protective properties. ### 3. **Independent of Weight Loss** The liver benefits of GLP-1RAs are not solely dependent on weight loss, which is a common effect of these drugs. Both obese and non-obese patients experienced reduced HCC risk, highlighting the direct impact of GLP-1RAs on liver health, independent of their metabolic effects. ### 4. **Enhanced Benefits in the Absence of Insulin** Patients who were not using insulin showed stronger liver-protective effects with GLP-1RA therapy. This observation suggests that insulin may exert negative influences on liver health, which are not entirely mitigated by GLP-1RAs when used in combination. ### 5. **Protection Across All Stages of Liver Disease** GLP-1RAs have demonstrated efficacy in reducing HCC risk across various stages of liver disease, including: - **MASLD/MASH** (Metabolic Associated Steatotic Liver Disease/Metabolic Associated Steatohepatitis) - **Fibrosis** - **Cirrhosis** This suggests that GLP-1RAs are effective in preventing liver disease progression and associated complications. ### 6. **Preventive Potential in Patients Without Liver Disease** Even in patients without pre-existing liver conditions (MASLD, MASH, or cirrhosis), GLP-1RA therapy reduced the risk of HCC. This underscores their preventive potential, making them valuable for liver health in broader patient populations. ### 7. **Substance Use Influence** GLP-1RAs significantly lowered HCC risk in patients who did not use alcohol or tobacco. However, in patients who did use these substances, the liver-protective effects were smaller and did not reach statistical significance. This suggests that lifestyle factors may influence the efficacy of GLP-1RAs in liver protection. ### 8. **Combination Therapy Advantage** When GLP-1RAs were combined with other diabetes medications such as SGLT2 inhibitors or thiazolidinediones, the benefits were enhanced: - **HCC Risk Reduction**: Combination therapy provided greater protection against liver cancer. - **Hepatic Decompensation Risk Reduction**: The combined use amplified the liver-protective effects beyond those seen with GLP-1RA monotherapy. ### 9. **Caution with Insulin Combination** The combination of GLP-1RAs and insulin was less effective in reducing HCC risk compared to GLP-1RA monotherapy. This suggests that insulin may have carcinogenic mechanisms that are not fully counteracted by GLP-1RAs. ### 10. **Real-World Evidence and Safety** In a large U.S. cohort study involving over 1.8 million patients, GLP-1RAs demonstrated robust liver-protective associations without increasing serious adverse events. This real-world evidence supports their safety and efficacy in managing liver-related risks in T2DM patients. ### Summary GLP-1 receptor agonists offer substantial liver protection in patients with type 2 diabetes, reducing the risk of HCC and hepatic decompensation across various stages of liver disease. Their benefits extend beyond weight loss and are enhanced when combined with other medications like SGLT2 inhibitors or thiazolidinediones. However, caution is warranted when using GLP-1RAs in combination with insulin, as the protective effects may be diminished. GLP-1RAs also show preventive potential in patients without liver disease and maintain their efficacy in real-world settings, making them a valuable option for liver health management in T2DM.

2D-SWE in MASLD

Two-dimensional shear wave elastography (2D-SWE) is a non-invasive imaging technique used to measure liver stiffness, which helps assess the severity of liver fibrosis. Liver fibrosis occurs when scar tissue builds up in the liver, often due to conditions like metabolic dysfunction-associated steatotic liver disease (MASLD), a liver condition linked to obesity and metabolic issues. Early detection of fibrosis is critical, as advanced stages (like cirrhosis) increase the risk of complications such as liver failure or cancer. 2D-SWE works by sending ultrasound waves into the liver and measuring how quickly shear waves travel through the tissue. Stiffer liver tissue, often caused by fibrosis, results in faster wave propagation. This method is gaining attention because it provides accurate, reproducible results and is relatively easy to perform. In MASLD, 2D-SWE is particularly useful because it overcomes some limitations of older techniques like vibration-controlled transient elastography (VCTE), which can be less accurate in obese patients. A recent meta-analysis has established standardized cutoff values for 2D-SWE to improve its diagnostic accuracy for different stages of fibrosis. By integrating 2D-SWE into clinical practice, healthcare providers can better identify high-risk MASLD patients, enabling earlier interventions and improved management of liver health.

A new generation of non-invasive tests of liver fibrosis in MASLD

The new generation of non-invasive tests (NITs) for liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) are advanced diagnostic tools developed using machine learning and multitargeting approaches. These tests aim to improve the accuracy and reliability of diagnosing advanced fibrosis (F3–F4) in MASLD patients, addressing the limitations of conventional NITs. ### 1. **New Generation Markers Developed:** Three new multitargeted NITs were introduced in the study: - **FIB-9**: A model based solely on commonly available blood parameters. - **FIB-11**: A model incorporating additional specialized fibrosis markers. - **FIB-12**: The most advanced model, combining blood-based markers with liver stiffness measurement (LSM). These models were developed using **ADORE machine learning software**, which optimized predictions across multiple fibrosis stages simultaneously, surpassing the accuracy of traditional single-target statistical methods. --- ### 2. **Performance of New Generation Markers:** - **FIB-12**: - Achieved the highest diagnostic accuracy at **83.3%** in binary classification (AUROC 0.912). - Outperformed conventional NITs like FIB-4, FibroTest, FibroMeter, ELF, and Elasto-FibroMeter (EFM), all of which had accuracies below 80%. - Demonstrated superior accuracy over traditional tests in both binary and ordinal segmentation analyses, with over **90% accuracy in 41.5% of patients**. - Showed robust performance across different patient subgroups, including those with diabetes, older age, or varying disease complexity. - Was particularly effective for diagnosing fibrosis stages F2–F3, which are critical therapeutic targets for emerging MASLD treatments like resmetirom. - **FIB-9**: - A practical and cost-effective option, relying on routine laboratory parameters. - Achieved accuracy comparable to commercial fibrosis panels (AUROC 0.863). - Available as a **free online calculator**, making it highly accessible for primary care and mass screening. - **FIB-11**: - Showed slightly reduced precision in older or diabetic populations but still demonstrated strong overall performance. - Can complement FIB-12 in quaternary segmentation strategies to enhance diagnostic reliability. --- ### 3. **Comparison with Conventional Markers:** Traditional NITs, such as FIB-4, FibroTest, FibroMeter, ELF, and LSM, have been widely used for assessing liver fibrosis. However, these tests often fall short in terms of diagnostic accuracy, particularly in MASLD, due to the metabolic complexity of the disease. For example: - FIB-4 and FibroTest typically have accuracy rates below 80%. - The ELF test demonstrated an AUROC of 0.865, which was significantly lower than FIB-12's AUROC of 0.912. The new generation models (FIB-9, FIB-11, and FIB-12) represent a significant advancement, providing higher accuracy, fewer indeterminate results, and enhanced clinical utility. --- ### 4. **Clinical Implications of New Generation Markers:** The development of these AI-based NITs has several key clinical implications: - **Improved Diagnostic Accuracy**: - The new models, particularly FIB-12, offer better precision for identifying advanced fibrosis, addressing the diagnostic gaps of traditional tests. - FIB-12 showed strong diagnostic performance for F2–F3 fibrosis, the therapeutic target range for MASLD treatments. - **Reduced Indeterminate Results**: - FIB-12 achieved the lowest indeterminate rate (16.4%) and the highest accuracy (up to 92%) in determinate cases when patients were classified into ruled-in, ruled-out, and indeterminate groups. - **Cost-Effectiveness and Accessibility**: - FIB-9, as a free online tool, enables healthcare providers to estimate fibrosis stage using basic lab results, making it ideal for mass screening and use in primary care settings. - **Enhanced Screening and Staging Efficiency**: - The multitarget design of the new models allows for more reliable staging of fibrosis, which is critical for clinical decision-making and treatment planning. - The **Fibs+ algorithm**, which integrates FIB-9, FIB-11, and FIB-12, outperformed existing clinical guidelines from the AGA, AASLD, and EASL for fibrosis detection. - **Broader Applicability Across Patient Populations**: - FIB-12 maintained high accuracy across different subgroups, including older patients and those with diabetes, ensuring its utility in diverse clinical settings. --- ### 5. **Conclusion:** The new generation of non-invasive tests—FIB-9, FIB-11, and FIB-12—represents a major advancement in the assessment of liver fibrosis in MASLD. These AI-enhanced models deliver significantly higher accuracy, fewer indeterminate results, and broader clinical utility compared to conventional NITs. Among these, **FIB-12** is the most accurate and reliable tool for advanced fibrosis diagnosis, while **FIB-9** offers a practical, cost-free option for mass screening. These tests are poised to improve clinical workflows, enhance early detection, and facilitate better management of MASLD.

Targeting Hepatic Stellate cells in MASH

Targeting hepatic stellate cells (HSCs) in metabolic dysfunction-associated steatohepatitis (MASH) represents a promising therapeutic approach to prevent or reverse liver fibrosis, a key driver of disease progression. Below is a detailed explanation of the context, mechanisms, and therapeutic strategies derived from the study: ### 1. **Role of Hepatic Stellate Cells in Fibrosis**: - **HSC Activation**: In healthy livers, HSCs exist in a quiescent state (Q), storing vitamin A and maintaining normal extracellular matrix (ECM) turnover. However, in MASH, chronic liver injury caused by metabolic dysfunction (e.g., lipotoxicity, inflammation) triggers HSC transdifferentiation into activated myofibroblast-like cells. - **Fibrogenic Myofibroblasts**: Once activated, HSCs (A1 and A2 phenotypes) proliferate and secrete fibrotic ECM components like collagen and fibronectin. This excessive ECM deposition leads to liver scarring (fibrosis), which impairs liver function and contributes to disease progression. ### 2. **Key Findings from the Study**: - **HSC Subpopulations**: The study identified four distinct HSC phenotypes—quiescent (Q), activated (A1 and A2), and inflammatory (INF). Activated HSCs (A1 and A2) were found to dominate in MASH livers, constituting 13–20% of total liver cells compared to only 4–8% in normal livers. - **Core Fibrogenic Genes**: Six genes—**SERPINE1, GAS7, SPON1, LTBP2, KLF9, and EFEMP1**—were identified as a core fibrogenic gene set driving HSC activation and fibrosis. These genes were upregulated and showed enhanced chromatin accessibility in activated HSCs. - **Pathway Enrichment**: These genes are involved in ECM organization and actin filament regulation, essential for fibrotic scar formation and HSC activation. - **RUNX1/2–SERPINE1 Axis**: The study discovered that the **RUNX1/2-SERPINE1 signaling axis** is a pivotal regulatory pathway promoting HSC activation and ECM deposition, making it a key therapeutic target. ### 3. **Therapeutic Strategies for Targeting HSCs**: - **Targeting SERPINE1 (PAI-1)**: - SERPINE1 encodes plasminogen activator inhibitor-1 (PAI-1), a protein that promotes ECM accumulation and fibrosis. - **Knockdown of SERPINE1** in 3D human MASH liver spheroid models using dicer-substrate siRNA (dsiRNA) significantly reduced fibrogenic marker expression (e.g., COL1A1, ACTA2, TIMP1). - In **in vivo mouse models**, genetic deletion or pharmacologic inhibition of PAI-1 protected against fibrosis induced by liver injury (e.g., CCl₄ or a western diet). - Blocking PAI-1 also inhibited TGFβ-driven fibrotic signaling, suggesting its potential as a therapeutic target. - **Targeting SPON1 and LTBP2**: - Silencing SPON1 and LTBP2 suppressed TGFβ signaling and ECM protein expression, confirming their roles in HSC activation and fibrogenesis. - **Epigenetic Modulation**: - Chromatin accessibility correlated strongly with the activation of fibrogenic genes. Targeting epigenetic regulators that maintain open chromatin at fibrogenic gene loci could prevent HSC activation. - **Transcription Factor Inhibition**: - The study highlighted three classes of transcription factors (TFs) regulating HSC activation: - **Lineage-specific TFs**: JUNB/AP-1. - **Cluster-specific TFs**: RUNX1/2. - **Signal-specific TFs**: FOXA1/2. - Disrupting the crosstalk between RUNX1/2 and FOXA1/2 could block the integration of mechanical (ECM) and cytokine (TGFβ) signals into fibrogenic transcriptional outputs. - **TGFβ Pathway Inhibition**: - TGFβ signaling is a major driver of HSC activation and fibrosis. Therapeutics targeting TGFβ signaling (e.g., inhibitors of TGFβ receptors or downstream effectors) could effectively reduce fibrosis. ### 4. **Validation of Therapeutic Targets**: - **Functional Validation**: - Knockdown of SERPINE1 in human MASH liver spheroids reduced fibrogenic markers, demonstrating its functional role in fibrosis. - **In Vivo Validation**: - In mouse models, genetic deletion or pharmacologic inhibition of PAI-1 prevented fibrosis under various liver injury conditions. - **Cross-Species Validation**: - The identified HSC subclusters and fibrogenic signatures in humans were closely mirrored in murine MASH models, highlighting the translational relevance of these findings. ### 5. **Mechanistic Insights**: - **Epigenetic Priming**: - Activation-associated genes in HSCs were epigenetically primed through open chromatin in promoter and enhancer regions, enabling rapid transcriptional responses to fibrogenic signals. - **Transcriptional Pseudotime Analysis**: - Trajectory analysis revealed a stepwise progression of HSCs from quiescent (Q) to activated states (A1 → A2), with the gradual acquisition of fibrogenic gene signatures. - **RUNX1/2 and FOXA1/2 Crosstalk**: - Mechanistic modeling suggested direct interaction between RUNX1/2 and FOXA1/2, integrating ECM and cytokine signals into fibrogenic transcriptional outputs. ### 6. **Therapeutic Potential**: - The study underscores the potential of targeting the RUNX1/2–SERPINE1 axis or downstream fibrogenic genes (e.g., SPON1, LTBP2, GAS7) as antifibrotic strategies in MASH. - By combining transcriptomic, epigenomic, and functional assays, the study provided a comprehensive understanding of HSC activation dynamics and identified concrete druggable pathways. ### 7. **Conclusion**: - Targeting hepatic stellate cells in MASH offers a promising therapeutic strategy to combat liver fibrosis. The identification of key regulatory pathways (e.g., RUNX1/2–SERPINE1 axis) and fibrogenic genes (e.g., SPON1, LTBP2) provides a solid foundation for developing antifibrotic therapies. - Future therapies could involve small-molecule inhibitors, RNA-based therapeutics (e.g., siRNA), or monoclonal antibodies targeting these pathways to prevent or reverse fibrosis in metabolic liver disease.

Plasma metabolomics prevents MASH related mortality

Plasma metabolomics, a branch of metabolomics focused on analyzing small molecules (metabolites) in blood plasma, plays a promising role in the prevention of metabolic dysfunction-associated steatohepatitis (MASH) and related liver mortality. This approach focuses on identifying biochemical changes and patterns in the blood that are linked to liver dysfunction, allowing for early detection, risk stratification, and targeted interventions. Below is a detailed explanation of how plasma metabolomics contributes to MASH prevention and mortality reduction: ### 1. **Understanding Plasma Metabolomics** - **Definition**: Plasma metabolomics involves the study of metabolites—small molecules such as lipids, amino acids, and carbohydrates—in blood plasma. These metabolites reflect ongoing physiological and pathological processes in the body. - **Tools**: Techniques like nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) are commonly used to analyze the metabolome in a cost-effective and scalable manner. - **Clinical Relevance**: Plasma metabolomics provides insights into systemic metabolic health, making it a valuable tool for understanding and managing metabolic disorders, including MASH. ### 2. **Role of Plasma Metabolomics in MASH Prevention** - **Early Detection**: Metabolomic profiling can identify biomarkers associated with liver dysfunction, such as elevated levels of tyrosine and specific lipid ratios (e.g., the phospholipids-to-total lipids ratio in very-low-density lipoproteins [V0PLp]). These biomarkers can detect MASH at an early stage before significant liver damage occurs. - **Risk Prediction**: By developing metabolome-derived scores (like the one created by Huang et al.), plasma metabolomics can accurately predict individuals at high risk of developing MASH or experiencing liver-related mortality. - **Personalized Interventions**: Identifying specific metabolic abnormalities allows clinicians to tailor interventions, such as dietary changes, weight management, or pharmacological treatments, to prevent disease progression. - **Monitoring Disease Progression**: Plasma metabolomics can be used to track changes in metabolic profiles over time, helping clinicians assess the effectiveness of interventions and adjust treatment strategies accordingly. ### 3. **Reducing MASH-Related Mortality** - **Prognosis and Outcome Prediction**: Plasma metabolomics-based scores have demonstrated high predictive accuracy for liver-related mortality. For example, Huang et al.'s model achieved AUROC values of 0.88 and 0.93 for MASLD-related mortality in validation cohorts, suggesting strong potential for identifying patients at risk of severe outcomes. - **Targeted Management**: By identifying at-risk individuals, healthcare providers can implement early and aggressive management strategies to prevent complications such as cirrhosis, liver failure, or hepatocellular carcinoma, which are major contributors to liver-related mortality. - **Mechanistic Insights**: Plasma metabolomics can provide a better understanding of the biochemical pathways involved in MASH and its progression, paving the way for novel therapeutic targets. ### 4. **Key Biomarkers in Plasma Metabolomics for MASH** - **Tyrosine**: Elevated plasma tyrosine levels have been consistently associated with liver dysfunction and long-term liver-related events. This aligns with prior evidence linking tyrosine to metabolic and inflammatory pathways relevant to MASH. - **Phospholipids-to-Total Lipids Ratio in V0PLp**: This novel biomarker captures lipid metabolism abnormalities associated with liver disease. While its exact biological role in MASH is not yet fully understood, it has shown strong predictive utility in Huang et al.'s model. - **Other Metabolites**: Additional metabolites, such as amino acids, bile acids, and lipid species, may also serve as potential biomarkers for MASH and liver-related outcomes. ### 5. **Advantages of Plasma Metabolomics** - **Non-Invasive**: Plasma metabolomics relies on blood samples, making it minimally invasive and more acceptable to patients compared to liver biopsies. - **Cost-Effective**: Techniques like NMR-based metabolomics are relatively affordable, enabling large-scale implementation in clinical settings. - **Scalability**: Plasma metabolomics can be integrated into routine clinical workflows, allowing for widespread screening and monitoring of at-risk populations. ### 6. **Challenges and Limitations** - **Validation Across Populations**: The predictive models need to be validated in diverse populations to ensure generalizability across ethnicities, disease etiologies, and healthcare settings. - **Mechanistic Understanding**: The biological rationale behind certain biomarkers, such as the V0PLp ratio, remains unclear and requires further research to strengthen confidence in their use. - **Clinical Utility**: While plasma metabolomics shows promise, its net diagnostic and clinical benefits in real-world settings have yet to be quantified. Decision curve analysis and other tools are needed to assess its impact on patient care. - **Standardization and Accessibility**: Translating metabolomics-based biomarkers into routine clinical practice requires standardized protocols, accessible technology, and trained personnel. ### 7. **Future Directions** - **Longitudinal Studies**: Further research is needed to evaluate how metabolomic profiles change over time and how these changes correlate with disease progression and outcomes. - **Integration with Other Biomarkers**: Combining plasma metabolomics with other diagnostic tools, such as imaging or genetic testing, could enhance predictive accuracy and clinical utility. - **Focus on Prevention**: By identifying individuals at risk of MASH early, plasma metabolomics could shift the focus from treatment to prevention, reducing the burden of liver-related mortality. ### 8. **Conclusion** Plasma metabolomics represents a transformative approach to preventing MASH and related mortality. By identifying and leveraging specific metabolic biomarkers, clinicians can detect MASH early, predict disease outcomes, and implement personalized interventions. However, challenges related to validation, standardization, and clinical utility must be addressed before metabolomics-based tools can be widely adopted in clinical practice. Despite these challenges, the integration of plasma metabolomics into healthcare holds great promise for advancing precision medicine in chronic liver disease management.

Exosome-related genes for MASLD-related HCC

Exosome-related genes have gained significant attention for their potential role in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD) to hepatocellular carcinoma (HCC). These genes are involved in the biogenesis, secretion, and function of exosomes, which are small extracellular vesicles that mediate intercellular communication. Below is a detailed explanation of the role of exosome-related genes in MASLD-related HCC: --- ### **What are Exosome-Related Genes?** Exosome-related genes are those involved in the biogenesis, secretion, and function of exosomes. Exosomes are vesicles released by cells that carry bioactive molecules such as proteins, lipids, and RNA. They are critical in intercellular communication and influence various biological processes, including immune responses, inflammation, and tumor progression. In the context of MASLD-related HCC, exosome-related genes regulate the secretion and content of exosomes, which can influence the tumor microenvironment, immune modulation, and metabolic reprogramming. --- ### **Role of Exosome-Related Genes in MASLD (NAFLD)** 1. **Progression from MASLD to HCC:** - MASLD is a metabolic liver disorder characterized by fat accumulation in the liver. It can progress to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and eventually HCC. - Exosome-related genes play a role in this progression by influencing intercellular signaling pathways that promote inflammation, fibrosis, and oncogenesis. 2. **Exosome-Mediated Communication:** - Exosomes facilitate communication between hepatocytes, immune cells, and the tumor microenvironment. This signaling can exacerbate liver damage, promote fibrosis, and create a pro-tumorigenic microenvironment. - For example, exosome cargo such as microRNAs (miRNAs) and proteins can activate pathways that drive inflammation and metabolic dysregulation in MASLD. 3. **Biomarker Potential:** - Exosome-related genes and the exosomes they regulate are being studied as non-invasive biomarkers for MASLD progression. They can help identify patients at risk of developing HCC from MASLD. --- ### **Correlation Between HCC and MASLD** 1. **MASLD as a Major Risk Factor for HCC:** - MASLD is one of the leading causes of HCC, especially in the absence of other risk factors such as viral hepatitis or alcohol abuse. - Chronic inflammation, oxidative stress, and metabolic dysregulation in MASLD create a favorable environment for hepatocarcinogenesis. 2. **Exosome-Driven Tumor Microenvironment:** - Exosomes derived from MASLD-affected hepatocytes can carry oncogenic signals, such as pro-inflammatory cytokines, miRNAs, and other molecules, which promote tumor initiation and progression. - Exosome-related genes contribute to this process by regulating the secretion of tumor-promoting exosomes. 3. **Immunomodulation:** - Exosome-related genes influence immune cell activity in MASLD and HCC. For example, exosomes can suppress anti-tumor immune responses by modulating T-cell activity and promoting immune checkpoint expression. --- ### **Exosome-Related Genes and MASLD-HCC Progression** A recent study identified three key exosome-related genes—**VPS45**, **VAMP5**, and **EXPH5**—that play a critical role in MASLD-HCC progression. These genes were used to construct a diagnostic and prognostic model for MASLD-HCC. 1. **VPS45 (Vacuolar Protein Sorting 45):** - Involved in the trafficking and secretion of exosomes. - High expression of VPS45 was observed in MASLD-HCC patients and was associated with increased immune cell infiltration and tumor progression. 2. **VAMP5 (Vesicle-Associated Membrane Protein 5):** - Plays a role in exosome biogenesis and vesicle transport. - Elevated VAMP5 expression correlated with poor prognosis and increased CD4⁺ T-cell infiltration in MASLD-HCC patients. 3. **EXPH5 (Exophilin 5):** - Regulates exosome secretion and cargo sorting. - Unlike VPS45 and VAMP5, EXPH5 expression was decreased in MASLD-HCC, suggesting a potential tumor-suppressive role. --- ### **How These Genes Influence MASLD-HCC** 1. **Diagnostic and Prognostic Value:** - A logistic regression model using VPS45, VAMP5, and EXPH5 was developed to predict MASLD-HCC progression: - **Risk score formula:** Risk score = 1/(1 + e⁻ᶻ), where Z = 1.238×VPS45 + 1.239×VAMP5 − 1.455×EXPH5 − 11.047. - This model achieved high diagnostic accuracy with an area under the curve (AUC) of 0.736 for distinguishing MASLD-HCC from non-tumor liver tissues. 2. **Immune Microenvironment Modulation:** - High-risk patients (based on the gene signature) showed increased infiltration of memory CD4⁺ T-cells but reduced expression of immune checkpoint molecules such as PD1, PDL1, and PDL2. This suggests an altered immune microenvironment that may contribute to immunotherapy resistance. 3. **Metabolic Reprogramming:** - Pathway enrichment analysis revealed that exosome-related genes are involved in metabolic pathways such as "carbon metabolism" and "drug metabolism–cytochrome P450," which are critical in tumorigenesis. 4. **Therapeutic Implications:** - High-risk MASLD-HCC patients showed greater sensitivity to certain chemotherapeutic agents (e.g., 5-fluorouracil, cisplatin, irinotecan), suggesting that the gene signature could guide personalized treatment strategies. --- ### **Key Findings and Clinical Implications** 1. **Non-Invasive Biomarkers:** - The VPS45–VAMP5–EXPH5 gene signature offers a non-invasive molecular tool for diagnosing and stratifying MASLD-HCC patients, improving early detection. 2. **Prognostic Value:** - High-risk patients identified by the gene signature had significantly worse overall survival, making it a reliable prognostic biomarker. 3. **Link to TP53 Mutations:** - High-risk MASLD-HCC patients had a higher prevalence of TP53 mutations, suggesting a link between exosome secretion regulation and TP53-driven oncogenesis. 4. **Potential for Precision Oncology:** - The study highlights the potential of combining exosome-related gene signatures with immunotherapy and chemotherapy for personalized treatment of MASLD-HCC. --- ### **Conclusion** Exosome-related genes, particularly VPS45, VAMP5, and EXPH5, play a pivotal role in the progression of MASLD to HCC. These genes influence exosome secretion, immune modulation, and metabolic reprogramming, making them valuable biomarkers and therapeutic targets. The development of a gene-based diagnostic and prognostic model represents a significant step forward in precision oncology for MASLD-HCC, offering new opportunities for early detection and personalized treatment strategies.

Normal ALT, Liver Fibrosis and MASLD

The study you provided investigates the relationship between normal ALT (alanine transaminase) levels, liver fibrosis, and metabolic dysfunction-associated steatotic liver disease (MASLD). Here's a detailed breakdown of the findings and implications for patients with normal ALT levels and liver fibrosis in the context of MASLD: --- ### **Key Insights:** 1. **Definition of Normal ALT in MASLD Patients:** - Persistently normal ALT levels were defined as three consecutive ALT measurements within the normal range over six months: - **Men:** <33 IU/L - **Women:** <25 IU/L - Elevated ALT levels were considered above these thresholds. 2. **Fibrosis Risk in Normal ALT Patients:** - Despite having normal ALT levels, MASLD patients can still have significant liver fibrosis. - Normal ALT levels may give a false impression of clinical stability, underestimating the risk of fibrosis progression. 3. **Fibrosis Regression in Normal ALT Patients:** - Compared to patients with elevated ALT and fibrosis, those with normal ALT and fibrosis showed **poorer fibrosis regression rates** (31.9% vs. 53.4%, p = 0.001). - This indicates that fibrosis in normal ALT patients is less likely to improve with lifestyle interventions. 4. **Lifestyle Intervention Requirements:** - Patients with normal ALT and fibrosis required **greater weight loss** and **steatosis reduction** to achieve fibrosis regression compared to those with elevated ALT: - **Weight Loss Threshold:** - 8.55% in normal ALT/fibrosis patients. - 4.94% in elevated ALT/fibrosis patients. - **Liver Fat Content (LFC) Reduction Threshold:** - 39.85% in normal ALT/fibrosis patients. - 20.57% in elevated ALT/fibrosis patients. - This suggests that patients with normal ALT may need more aggressive lifestyle changes to achieve similar outcomes. 5. **Mechanistic Explanation:** - **Normal ALT Levels:** - May reflect quiescent hepatic stellate cells (HSCs) and reduced macrophage activation. - This limits collagen degradation and fibrosis reversal, making fibrosis regression more difficult. - **Elevated ALT Levels:** - Associated with active hepatocyte repair and extracellular matrix remodeling. - This explains why fibrosis regression is more pronounced in elevated ALT patients. 6. **Inflammation and Fibrosis Improvement:** - Elevated high-sensitivity C-reactive protein (hs-CRP >2.0 mg/L) was linked to greater fibrosis improvement, particularly in normal ALT/fibrosis patients. - This suggests that inflammation may play a role in fibrosis dynamics, even in patients with normal ALT. 7. **Stage-Specific Effects:** - ALT elevation predicted fibrosis regression primarily in early fibrosis stages (F1–F2). - In advanced fibrosis stages (F3–F4), structural liver damage becomes irreversible, and ALT levels were less predictive of improvement. --- ### **Clinical Implications for Normal ALT Patients:** 1. **Aggressive Management Required:** - Patients with MASLD and normal ALT levels, especially those with fibrosis, require **intensified lifestyle interventions** (e.g., stricter caloric restriction and more physical activity). - Pharmacologic treatments may also be needed in these patients to address the higher effort required for fibrosis regression. 2. **Non-Invasive Monitoring:** - Combining MRI-proton density fat fraction (MRI-PDFF) for liver fat content and 2D-shear wave elastography (2D-SWE) for fibrosis provides a reliable, non-invasive alternative to liver biopsy. - These tools can help monitor steatosis and fibrosis changes over time in normal ALT patients. 3. **Risk Awareness:** - Patients with normal ALT levels should not be considered "low risk" for fibrosis progression. - Clinicians should be vigilant in assessing fibrosis status and tailoring interventions accordingly. 4. **Inflammation as a Target:** - Elevated hs-CRP levels in normal ALT patients suggest that targeting systemic inflammation may enhance fibrosis regression. --- ### **Study Limitations:** - Single-center design and predominance of male participants (72%) may limit generalizability. - Self-reported adherence to lifestyle interventions could introduce bias. - Serial ALT trend tracking and biomarkers were not included, which could refine predictive models. --- ### **Conclusion:** MASLD patients with normal ALT levels are at significant risk for liver fibrosis and show poorer fibrosis regression compared to those with elevated ALT. Achieving fibrosis improvement in these patients requires greater weight loss and steatosis reduction, underscoring the need for aggressive management strategies and close monitoring. Non-invasive imaging techniques like MRI-PDFF and 2D-SWE should be utilized for tracking treatment progress, and future research should focus on refining predictive models with multicenter cohorts and advanced biomarkers.

Rapamycin alleviate intrahepatic inflammation in MASLD

Yes, rapamycin alleviates intrahepatic inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD). According to the study, rapamycin's therapeutic effects are primarily mediated through its action on bone marrow-derived macrophages, which are key immune cells involved in liver inflammation. Rapamycin suppresses the proinflammatory activation of hepatic macrophages and enhances pathways related to fatty acid oxidation within these cells. By promoting fatty acid oxidation in macrophages, rapamycin reduces their inflammatory capacity, thereby creating a less inflammatory hepatic microenvironment. This reprogramming of macrophage metabolism toward an anti-inflammatory state is a key mechanism by which rapamycin mitigates intrahepatic inflammation in MASLD. Thus, rapamycin offers a promising approach to targeting inflammation in MASLD and its advanced form, metabolic dysfunction-associated steatohepatitis (MASH). However, it is important to note that while rapamycin improves hepatic inflammation, steatosis, and steatohepatitis, it does not have a significant impact on established liver fibrosis.

Fisetin against the development of MAFLD

Fisetin, a natural flavonoid found in fruits and vegetables like strawberries and apples, has shown significant potential in combating metabolic dysfunction-associated fatty liver disease (MAFLD). MAFLD, a chronic liver condition linked to obesity, insulin resistance, and type 2 diabetes, affects nearly 30% of the global population. In a study using a high-fat diet (HFD)-induced mouse model and sodium oleate (OA)-treated HepG2 cells, fisetin demonstrated remarkable therapeutic effects against MAFLD progression. Fisetin significantly reduced body weight gain, liver mass, and fat accumulation in HFD-fed mice without altering food intake, indicating metabolic improvement. It improved blood glucose levels, glucose tolerance, and lipid profiles, including lowering triglycerides, total cholesterol, and LDL-C while increasing protective HDL-C levels. Fisetin also enhanced liver function by reducing serum AST and ALT levels, markers of hepatic injury. Histological analyses confirmed reduced hepatic lipid accumulation and increased glycogen storage, reflecting improved glucose utilization and suppressed gluconeogenesis. Fisetin restored antioxidant balance by enhancing superoxide dismutase (SOD) activity and reducing reactive oxygen species (ROS) and nitric oxide (NO) levels. Mechanistically, fisetin activated the GSK-3β/Nrf2/HO-1 pathway, upregulated antioxidant enzymes, and downregulated gluconeogenic enzymes (PEPCK, G6PC), promoting glucose and lipid homeostasis. These findings suggest fisetin as a promising natural therapeutic for MAFLD.

Survodutide - Role in MASH

Survodutide is emerging as a promising treatment for metabolic dysfunction–associated steatohepatitis (MASH), a progressive form of metabolic dysfunction–associated steatotic liver disease (MASLD). Survodutide functions as a dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors, targeting both metabolic and hepatic pathways central to MASH pathology. By activating GLP-1 receptors, Survodutide reduces appetite and improves insulin resistance, while glucagon receptor activation decreases liver fat production, potentially reversing key aspects of MASH. In a 48-week multicenter trial involving 293 patients with biopsy-confirmed MASH, Survodutide demonstrated robust efficacy. Between 43–62% of patients treated with Survodutide achieved histologic resolution of MASH, compared to 14% in the placebo group. Furthermore, over 57% of participants experienced at least a 30% reduction in liver fat, highlighting its strong metabolic and hepatic benefits. These outcomes underscore the drug’s potential in addressing both liver inflammation and fat accumulation, critical drivers of MASH progression. Despite its efficacy, Survodutide’s safety profile revealed notable gastrointestinal adverse effects, including nausea, vomiting, and diarrhea. These side effects led to treatment discontinuation in approximately 20% of patients, significantly higher than the 3% discontinuation rate in the placebo group. Survodutide’s promising results align with findings from tirzepatide, another dual receptor agonist targeting GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). Both drugs significantly outperform prior MASH treatments, offering hope for future combination or sequential therapies. However, larger, longer-term studies are needed to confirm Survodutide’s sustained benefits and long-term safety, particularly in diverse patient populations.

Efruxifermin and MASH

Efruxifermin (EFX) is a promising treatment for metabolic dysfunction-associated steatohepatitis (MASH), a severe progression of metabolic liver disease with limited effective therapies. EFX is a fibroblast growth factor 21 (FGF21) analogue that offers dual benefits for both liver and metabolic health. It works by regulating lipids, improving insulin sensitivity, and reducing inflammation. In a systematic review of four phase 2 clinical trials involving 450 participants with biopsy-confirmed MASH, EFX was evaluated for its safety and efficacy. Administered weekly via subcutaneous injection at doses of 28 mg or 50 mg, EFX showed significant improvements in liver health and metabolic parameters over 12 to 96 weeks. EFX reduced liver enzyme levels (ALT, AST, GGT) and hepatic fat fraction (HFF) by 54% to 62%, with some patients achieving complete normalization of liver fat. It also improved liver fibrosis and resolved MASH in many cases. Non-invasive markers of fibrosis, such as ELF scores and liver stiffness, showed notable reductions, confirming its antifibrotic effects. Metabolically, EFX improved HbA1c, insulin resistance, triglycerides, LDL-C, and increased HDL-C and adiponectin. The 50 mg dose led to modest weight loss, while the 28 mg dose focused on metabolic improvements without significant weight changes. Though EFX caused mild-to-moderate gastrointestinal side effects like nausea and diarrhea, it was generally well-tolerated. Compared to other therapies like GLP-1 receptor agonists, EFX demonstrated stronger effects on liver histology and fibrosis. Efruxifermin offers a comprehensive therapeutic approach for MASH, addressing liver, metabolic, and inflammatory aspects, making it a leading candidate for future treatment. Phase 3 trials are ongoing to confirm its long-term benefits.

Rising Global Burden of MASLD

The global burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as NAFLD, is rising at an alarming rate and poses a significant public health challenge. MASLD is now the most common chronic liver disease worldwide, affecting approximately 1.27 billion people in 2021, with a prevalence rate of 15,018 per 100,000 population. It is closely linked to obesity, type 2 diabetes mellitus (T2DM), and cardiovascular diseases, reflecting its intricate connection with other metabolic disorders. Over the past two decades (2000–2021), MASLD prevalence has increased by 75%, driven by global lifestyle changes, dietary transitions, and rising obesity rates. Although its prevalence has surged, the overall disability burden (measured in disability-adjusted life years or DALYs) has remained relatively stable compared to other metabolic diseases. However, significant regional disparities exist. The Eastern Mediterranean region has the highest MASLD prevalence, while the Americas bear the greatest disability burden. Middle-income countries, particularly in low-middle socioeconomic strata, experience the highest burden due to limited healthcare access and preventive measures. Sex-based differences reveal that males face a higher overall burden, but the rate of increase in MASLD is slightly higher in females. The pandemic has likely exacerbated this burden through sedentary lifestyles and disrupted healthcare services. MASLD is intricately linked with other metabolic diseases like T2DM and obesity, acting as both a consequence and a risk amplifier. Urgent public health efforts, such as lifestyle interventions, early screening, and better healthcare access, are needed to address this escalating global crisis. Recognizing MASLD as a major public health threat is critical for reducing its impact.

Spleen-To-Liver Stiffness Ratio in MASH

The spleen-to-liver stiffness ratio (SSM/LSM) is an emerging noninvasive biomarker that has shown significant potential in characterizing portal hypertension (PH), particularly in patients with metabolic dysfunction-associated steatohepatitis (MASH). Here is a detailed breakdown of the findings related to SSM/LSM in MASH based on the context provided: --- ### **1. Key Observations:** - **Higher SSM/LSM Ratio in MASH:** Patients with MASH exhibited a significantly higher spleen-to-liver stiffness ratio (median 1.66) compared to patients with alcohol-related liver disease (ALD) (median 1.28, p = 0.001). This suggests that spleen stiffness increases disproportionately relative to liver stiffness in MASH. - **Comparison to PSVD:** MASH values approached those seen in porto-sinusoidal vascular disease (PSVD), which had the highest SSM/LSM ratio (median 3.19). This supports the hypothesis that MASH includes a presinusoidal component of PH, similar to PSVD. - **Independence from Comorbidities:** After adjusting for factors like body mass index (BMI), diabetes, hypertension, and statin use, MASH remained an independent predictor of a higher SSM/LSM ratio (β = 0.59, p = 0.046). This indicates that the elevated ratio is specific to the vascular characteristics of MASH and not merely a result of metabolic comorbidities. --- ### **2. Clinical and Mechanistic Insights:** - **Presinusoidal Component in MASH:** The elevated SSM/LSM ratio in MASH reflects a presinusoidal component of PH that is not captured by traditional hepatic venous pressure gradient (HVPG) measurements. This presinusoidal PH is likely due to periportal vascular injury, ductular reaction, and portal fibrosis, which elevate splenic pressure independently of sinusoidal resistance. - **Early Detection of Portal Hypertension:** MASH patients exhibited higher SSM/LSM ratios even at lower HVPG levels, suggesting that the spleen stiffness-to-liver stiffness relationship could serve as an early indicator of portal venous pressure elevation before significant hepatic fibrosis develops. This is crucial for early detection and management of PH in MASH. - **Spleen Size Correlation:** Despite having less severe liver disease (lower MELD and HVPG scores), MASH patients had equal or slightly larger spleen diameters compared to ALD patients. When adjusted for HVPG, spleen size per pressure unit was significantly greater in MASH (1.15 cm/mmHg vs. 0.85 cm/mmHg, p < 0.001), further highlighting the presinusoidal vascular changes in MASH. --- ### **3. Prognostic Implications:** - **Risk of Hepatic Decompensation:** Patients with MASH and higher SSM/LSM ratios demonstrated a numerically higher risk of hepatic decompensation (13–18% at 6–12 months) compared to those with lower ratios. Although not statistically significant (p = 0.67), this suggests potential prognostic value for SSM/LSM in identifying patients at greater risk of complications. - **Distinct Hemodynamic Patterns:** The inverse correlation between the SSM/LSM ratio and HVPG (R = −0.35) indicates that as presinusoidal PH increases, the ratio rises despite lower HVPG values. This confirms the distinct hemodynamic patterns in MASH compared to other liver disease etiologies. --- ### **4. Comparison Between MASH and ALD:** - **Different PH Mechanisms:** ALD patients showed more severe intrahepatic fibrosis (higher LSM values), while MASH patients had greater extrahepatic pressure gradients (higher SSM/LSM ratios). This reinforces the idea that MASH and ALD have different mechanisms of portal hypertension, with MASH being more influenced by presinusoidal vascular changes. - **Correlation with HVPG:** While both LSM and SSM correlated significantly with HVPG across all etiologies (R = 0.54 and 0.42, respectively), the correlation was stronger in MASH (R = 0.62 for LSM and 0.55 for SSM). This indicates that these metrics are particularly effective in tracking PH severity in MASH. --- ### **5. Potential as a Noninvasive Biomarker:** The SSM/LSM ratio has the potential to serve as a novel imaging biomarker for identifying MASH patients with early or mixed-type PH. This could reduce reliance on invasive HVPG testing and provide a more comprehensive understanding of portal dynamics in metabolic liver disease. --- ### **6. Limitations and Future Directions:** - **Small MASH Sample Size:** The study included only 49 MASH patients, which limits the generalizability of the findings. Larger cohorts are needed to validate the results. - **Lack of Histological Validation:** The study did not include histological confirmation of presinusoidal fibrosis, which would strengthen the mechanistic insights. - **Absence of Direct Portal Pressure Measurements:** While HVPG is the gold standard for measuring portal pressure, it does not adequately capture presinusoidal PH. Future studies could incorporate direct portal pressure measurements to better understand the relationship between SSM/LSM and PH. --- ### **7. Conclusion:** The spleen-to-liver stiffness ratio (SSM/LSM) is a valuable noninvasive marker for detecting presinusoidal components of portal hypertension in MASH. It highlights unique vascular characteristics in MASH, such as early portal venous pressure elevation and splenomegaly, which are not captured by traditional HVPG measurements. This ratio could enhance the diagnosis, risk stratification, and management of portal hypertension in metabolic liver disease, marking a shift toward more precise, etiology-specific assessment of portal dynamics.

GLP-1 and GLP-1/GIP Agonists, Adverse Liver Outcomes and Type 2 DM

GLP-1 receptor agonists (such as semaglutide and liraglutide) and the dual GLP-1/GIP receptor agonist tirzepatide have been studied for their impact on major adverse liver outcomes (MALO) in patients with type 2 diabetes (T2D). These outcomes include severe liver conditions like cirrhosis, liver failure, hepatocellular carcinoma (HCC), and liver transplant, which are often linked to metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD is a growing concern globally, as its progression to cirrhosis and severe liver complications is closely tied to the severity of liver fibrosis. GLP-1 receptor agonists and dual GLP-1/GIP agonists have shown promise in improving metabolic health and reducing liver inflammation and fibrosis in previous studies. In a large-scale real-world study using data from over 150 million patients, researchers compared tirzepatide, semaglutide, and liraglutide with DPP-4 inhibitors over a two-year follow-up period. Tirzepatide demonstrated the strongest protective effect, with a 47% lower risk of MALO compared to DPP-4 inhibitors, primarily by reducing cirrhosis and decompensated cirrhosis cases. Semaglutide also significantly reduced MALO risk, particularly for decompensated cirrhosis and hepatic encephalopathy. Liraglutide, however, did not show significant overall benefits, except for a slight reduction in ascites incidence. The dual mechanism of tirzepatide (GLP-1 + GIP agonism) likely provides synergistic benefits by improving lipid metabolism, insulin sensitivity, and reducing hepatic inflammation and fibrosis. Both tirzepatide and semaglutide also improve glycemic control, body weight, and lipid profiles, further contributing to liver protection. These findings suggest prioritizing tirzepatide or semaglutide for managing MASLD in T2D patients, with tirzepatide showing the most promise in reducing adverse liver outcomes.

Non-invasive score, Advanced fibrosis and MASLD

Non-invasive scores, advanced fibrosis, and metabolic dysfunction-associated steatotic liver disease (MASLD) are interrelated concepts in the context of liver disease diagnosis and management. Here's a detailed explanation of these terms and their relevance based on the provided context: --- ### **1. Non-Invasive Scores:** Non-invasive fibrosis scoring tools are diagnostic methods designed to assess liver fibrosis severity without requiring a liver biopsy. These tools are based on clinical and laboratory parameters and are widely used due to their safety, cost-effectiveness, and accessibility. The study evaluated the following four non-invasive scoring tools: - **Fibrosis-4 (Fib-4):** Incorporates age, AST (aspartate aminotransferase), ALT (alanine aminotransferase), and platelet count. It is particularly effective in younger patients for ruling out advanced fibrosis, with an excellent negative predictive value (NPV) of 97.5% in this group. However, its sensitivity (10%) is poor overall, making it less effective for confirming advanced fibrosis. - **Nonalcoholic Fatty Liver Disease Fibrosis Score (NFS):** Includes variables such as age, BMI, AST/ALT ratio, platelet count, and albumin. It has strong NPV (96.5%) for excluding advanced fibrosis but suffers from low sensitivity (50%) and specificity (54%). Indeterminate results are common, especially in older adults. - **AST-to-Platelet Ratio Index (APRI):** A simple score based on AST levels and platelet count. It has balanced sensitivity (72.7%) and excellent NPV (97.6%), making it useful for excluding advanced fibrosis. However, its specificity (50.2%) and overall discriminatory accuracy (AUROC 51.2%) are suboptimal. - **BARD Score:** Combines BMI, AST/ALT ratio, and diabetes status. It has a sensitivity of 72.7% and an NPV of 95.5%, but its specificity (37.2%) and positive predictive value (PPV) (6.9%) are very low, limiting its ability to confirm advanced fibrosis. These scores are primarily used as **screening tools** to rule out advanced fibrosis and reduce the need for liver biopsies in primary care settings. --- ### **2. Advanced Fibrosis:** Advanced fibrosis refers to severe scarring of the liver, categorized as stages F3 and F4 in the Metavir scoring system. F3 indicates bridging fibrosis, while F4 represents cirrhosis, the most advanced stage of liver fibrosis. Advanced fibrosis is a critical stage because it significantly increases the risk of liver-related complications, such as liver failure, portal hypertension, and hepatocellular carcinoma (HCC). In the study, the prevalence of advanced fibrosis was relatively low (~4–6%) in the cohort. This low prevalence contributed to the poor positive predictive values (PPVs) of the non-invasive scores, as false positives were frequent. Despite this limitation, the high NPVs of these tools (all above 90%) make them effective for **excluding advanced fibrosis**, particularly in younger patients. --- ### **3. MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease):** MASLD is a recently introduced term that encompasses liver diseases previously classified under nonalcoholic fatty liver disease (NAFLD). MASLD is characterized by the accumulation of fat in the liver (steatosis) in the presence of metabolic dysfunction, such as obesity, diabetes, hypertension, and dyslipidemia. When inflammation and liver cell damage are also present, the condition is referred to as metabolic dysfunction-associated steatohepatitis (MASH), which is more severe and associated with a higher risk of fibrosis progression. The study cohort consisted of patients with biopsy-proven MASLD or MASH. Key demographic characteristics included: - Mean age: 53 years - Female predominance: 62% - High prevalence of obesity (75%), hypertension (63%), diabetes, and dyslipidemia, consistent with metabolic syndrome. --- ### **Key Findings and Clinical Implications:** 1. **Role of Non-Invasive Scores in MASLD/MASH:** - Non-invasive scores like Fib-4, NFS, APRI, and BARD are valuable tools for initial screening of fibrosis in MASLD/MASH patients. - These scores are particularly effective in ruling out advanced fibrosis due to their high NPVs (>90%), which can help reduce the need for invasive liver biopsies. 2. **Limitations in Confirming Advanced Fibrosis:** - All four scores had poor sensitivity and specificity for identifying advanced fibrosis, limiting their utility as standalone confirmatory tests. - The low prevalence of advanced fibrosis in the study population (~4–6%) further contributed to their poor PPVs. 3. **Age-Related Considerations:** - Age ≥45 years was identified as a significant determinant of fibrosis severity. Older adults with metabolic risk factors (e.g., diabetes and obesity) had a higher prevalence of advanced fibrosis. - However, the inclusion of age in scoring formulas may lead to overestimation of fibrosis in older adults, necessitating adjusted cutoffs or the use of complementary imaging techniques like transient elastography. 4. **Integration with Advanced Non-Invasive Tests:** - To improve diagnostic accuracy, the study recommends combining these scores with advanced non-invasive tools such as: - **Enhanced Liver Fibrosis (ELF) test** - **Agile 3+/4 scores** - **Transient elastography (FibroScan)** - These advanced modalities provide more precise staging of fibrosis and are valuable for comprehensive evaluation and management of MASLD/MASH. --- ### **Conclusion:** Non-invasive fibrosis scores (Fib-4, NFS, APRI, and BARD) play a critical role in the management of MASLD/MASH by effectively excluding advanced fibrosis, particularly in younger patients. However, their limited sensitivity, specificity, and confirmatory power necessitate integration with advanced diagnostic tools for accurate staging and risk stratification. Age and metabolic risk factors should also be considered when interpreting these scores, as they significantly influence fibrosis progression and diagnostic accuracy.

Invasive and noninvasive liver disease assessments and long-term clinical outcomes in MASLD

The study you’ve referenced investigates the utility of invasive and noninvasive liver disease assessments in predicting long-term clinical outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Below is a detailed breakdown of the findings and clinical implications: ### Study Overview: - **Purpose:** The study aimed to evaluate the predictive performance of both invasive (liver biopsy) and noninvasive (FIB-4 index) fibrosis assessments in forecasting long-term major adverse liver outcomes (MALO) and major adverse cardiovascular events (MACE) in MASLD patients. - **Design:** This was a long-term observational cohort study spanning 46 years (1974–2020) involving 959 Swedish adults with biopsy-confirmed MASLD. The cohort was followed for up to 15 years, with outcomes tracked using clinical and registry data. --- ### Key Findings: #### 1. **Fibrosis as the Key Prognostic Factor in MASLD:** - **Fibrosis stage** was identified as the strongest predictor of long-term liver-related outcomes (MALO). - Patients with mild fibrosis (F0–F2) had significantly lower risks of liver-related complications compared to those with cirrhosis (F4). - The risk difference between advanced fibrosis (F3) and cirrhosis (F4) was not statistically significant, indicating that progression beyond advanced fibrosis substantially increases the likelihood of adverse liver outcomes. #### 2. **Histological Features and Cardiovascular Outcomes:** - Other liver histological features, such as steatosis, inflammation, or ballooning, were not independently associated with MALO or MACE. - Neither fibrosis stage nor other histologic parameters were significantly linked to cardiovascular events. This suggests that while fibrosis is critical for predicting liver outcomes, it does not predict cardiovascular outcomes in MASLD. #### 3. **Noninvasive vs. Invasive Predictive Performance:** - The noninvasive **Fibrosis-4 (FIB-4) index** demonstrated comparable accuracy to biopsy-defined fibrosis staging for predicting liver outcomes. - **C-index for MALO prediction:** - Biopsy: 0.77 - FIB-4: 0.75 - Both methods performed modestly in predicting cardiovascular outcomes: - **C-index for MACE prediction:** - Biopsy: 0.58 - FIB-4: 0.65 - This underscores the utility of FIB-4 as a practical, noninvasive tool for long-term risk stratification in MASLD. --- ### Clinical Implications: 1. **Liver Fibrosis Drives Hepatic Outcomes:** - The severity of liver fibrosis, rather than other histologic features, determines long-term liver-related risks in MASLD. - This highlights the importance of assessing fibrosis stage in MASLD management. 2. **FIB-4 as a Reliable Noninvasive Alternative:** - The FIB-4 index is validated as a reliable, accessible alternative to liver biopsy for assessing fibrosis and predicting liver-related outcomes. - Routine FIB-4 assessments can enhance noninvasive prognostic evaluation, reducing the need for invasive biopsies in many cases. 3. **Limited Cardiovascular Predictive Value:** - Neither biopsy nor FIB-4 demonstrated strong predictive performance for cardiovascular outcomes, suggesting that other factors or tools are needed to assess cardiovascular risks in MASLD patients. 4. **Clinical Decision-Making:** - The findings support the integration of FIB-4 in routine clinical practice for MASLD management, particularly for identifying individuals at high risk of cirrhosis-related complications. - Noninvasive tools like FIB-4 can guide monitoring, treatment prioritization, and timing of interventions. --- ### Conclusion: This study underscores the critical role of liver fibrosis severity in determining long-term hepatic outcomes in MASLD. It validates the FIB-4 index as a practical, noninvasive alternative to biopsy for risk stratification. While fibrosis is a key driver of liver-related outcomes, it does not predict cardiovascular events, highlighting the need for separate cardiovascular risk assessments in MASLD patients. Overall, the findings have important implications for improving clinical care, minimizing the need for invasive procedures, and optimizing long-term management strategies in MASLD.

Non invastive criteria for pharmacotherapy in MASLD

Noninvasive criteria for pharmacotherapy in MASLD (Metabolic dysfunction-associated steatotic liver disease) have been a critical focus due to the limitations of existing diagnostic models. Current noninvasive clinical criteria for determining eligibility for resmetirom therapy in MASLD patients with F2–F3 fibrosis have shown significant inaccuracies and unreliability. Studies reveal that only 39% (Expert Panel) to 56% (AASLD Guidance) of biopsy-confirmed eligible patients meet these criteria, leading to substantial under-diagnosis and under-treatment. Existing guidelines demonstrate low sensitivity and specificity, with false-positive rates ranging from 23–41% and false-negative rates of 44–60%, resulting in poor diagnostic accuracy (AUC <0.60). Consequently, nearly half of the patients requiring treatment are left untreated. To address these limitations, researchers have developed a new two-step diagnostic strategy. This approach involves the initial selection of patients with FIB-4 ≥1.30 or, for those with FIB-4 <1.30, patients with diabetes and overweight. The second step uses liver stiffness measurement (LSM) via elastography (8–25 kPa) to confirm fibrosis stage and treatment eligibility. This refined model significantly improves diagnostic accuracy, achieving a positive predictive value of 55%, negative predictive value of 77%, and an AUC of 0.67, correctly identifying 74% of the true F2–F3 population. The two-step strategy integrates metabolic risk factors with fibrosis assessment, offering a more accurate, accessible, and reproducible framework for identifying MASLD patients eligible for pharmacotherapy. This ensures better patient selection, addressing the under-treatment issue and improving real-world clinical outcomes for MASLD management.

MASLD Consensus 2025

The **MASLD Consensus 2025** represents a unified and standardized approach to the management of **Metabolic dysfunction-associated steatotic liver disease (MASLD)** and **Metabolic dysfunction-associated steatohepatitis (MASH)**. This consensus was developed using expert opinions and the Delphi methodology to address discordances across existing guidelines and provide globally applicable recommendations. Below is a detailed breakdown of the key aspects of the MASLD Consensus 2025: --- ### **Core Objective** - To simplify and unify global guidelines for the screening, diagnosis, and management of MASLD and MASH. - The consensus aims to harmonize care worldwide, ensuring early detection, consistent management, and improved research comparability. --- ### **Study Scope** - 61 national and international guidelines from 2018 to 2025 were reviewed to identify inconsistencies and resolve discordances. - After four Delphi rounds, 46 final consensus statements achieved 100% agreement among experts. --- ### **Epidemiology** - MASLD affects approximately **38% of adults globally**. - MASH, the progressive form of MASLD, has a prevalence of **5%–7%**. --- ### **Major Risk Factors** - **Type 2 diabetes (T2D)**, **obesity**, and **persistent elevated aminotransferases** are the key indicators for evaluating MASLD. - These risk factors are central to identifying individuals at higher risk of liver disease progression. --- ### **Screening Recommendations** - **Who to screen:** Individuals with: - Type 2 diabetes. - Obesity. - Chronic liver enzyme elevation lasting ≥6 months. - **Alcohol thresholds:** To differentiate MASLD from alcohol-associated liver disease: - Women: ≤20g/day alcohol intake. - Men: ≤30g/day alcohol intake. - **Met-ALD classification:** Recognized as a subset of MASLD for individuals with moderate alcohol intake and metabolic risk factors. --- ### **Diagnostic Tools** 1. **Primary Diagnostic Tool:** - **Fibrosis-4 (FIB-4) test** is the first-line, noninvasive assessment for liver fibrosis. - **<1.3:** Indicates low risk of fibrosis. - **≥1.3:** Requires further assessment. - Regional adjustment: In India, a lower FIB-4 threshold of **1.0** is adopted due to population-specific variability. 2. **Secondary Assessment:** - **Vibration-controlled transient elastography (VCTE)** is recommended as the second-line test for evaluating liver stiffness and fibrosis grading. --- ### **Management Strategies** 1. **Lifestyle Modifications:** - **Weight loss:** Aim for a **5%–10% reduction** in body weight. - **Diet:** Emphasis on a **Mediterranean-style diet**. - **Physical activity:** Engage in **150–300 minutes of exercise per week** and reduce sedentary time. 2. **Comorbidity Management:** - Optimize control of: - Type 2 diabetes. - Dyslipidemia. - Cardiovascular risk factors (based on global cardiometabolic guidelines). 3. **Pharmacologic Guidance:** - **GLP-1 receptor agonists** and **SGLT-2 inhibitors** are preferred for managing T2D and obesity in MASLD patients. However, these are not yet approved as direct MASH therapies. - **Vitamin E:** Not recommended for routine MASH therapy due to limited efficacy and safety concerns. 4. **New Therapy Inclusion:** - **Resmetirom (THR-β agonist):** Recognized as the first FDA-approved drug for MASH with stage F2–F3 fibrosis. - **Monitoring:** Safety checks at 3, 6, and 12 months. - **Efficacy:** Assessed at 1 year using non-invasive tests (NITs)—a reduction in ALT alone is not considered a success criterion. 5. **Bariatric Surgery:** - Recommended for non-cirrhotic MASH patients who meet surgical criteria. - Not considered a primary treatment for MASH but can significantly improve liver outcomes. --- ### **Hepatocellular Carcinoma (HCC) Screening** - **For MASLD-related cirrhosis:** Screening every 6 months is recommended. - **For non-cirrhotic high-risk patients:** An individualized screening approach is advised. --- ### **Global Implications** - The MASLD Consensus 2025 introduces a **standardized algorithm** for the management of MASLD and MASH. - This harmonization is expected to: - Facilitate early detection of MASLD and MASH. - Ensure consistent management practices worldwide. - Improve comparability in clinical research, fostering advancements in treatment and care. --- ### **Conclusion** The MASLD Consensus 2025 provides a comprehensive, evidence-based framework for the global management of MASLD and MASH. By addressing discrepancies in screening, diagnosis, and treatment guidelines, the consensus aims to improve patient outcomes and advance the field of metabolic liver diseases.

New Canadian obesity pharmacotherapy guidelines

The new Canadian obesity pharmacotherapy guidelines represent a significant update to the approach for managing obesity in adults. These guidelines, which will remain in effect until May 2025, incorporate the latest evidence and reflect a comprehensive, patient-centered, and multidisciplinary strategy for treating obesity as a chronic and complex disease. Below is a detailed breakdown of the key aspects of the updated guidelines: ### 1. **Holistic Treatment Model** - Obesity care is framed around three pillars: **pharmacotherapy**, **behavioral/psychological interventions**, and **surgical approaches**. - The guidelines emphasize that pharmacotherapy is not a stand-alone treatment; it must be integrated with lifestyle modifications like nutrition, physical activity, and psychosocial support. ### 2. **Beyond BMI Alone** - The guidelines move beyond using Body Mass Index (BMI) as the sole determinant for initiating obesity treatment. - They recommend considering **measures of central adiposity** (e.g., waist circumference), **ethnicity-specific BMI thresholds**, and the presence of **adiposity-related complications** (e.g., cardiovascular disease, obstructive sleep apnea) to make more individualized and equitable treatment decisions. ### 3. **Individualized and Patient-Centered Care** - Treatment plans must be tailored to each individual's unique health needs, values, and preferences. - The focus is on improving outcomes such as **quality of life**, **mobility**, **energy levels**, **sleep quality**, and **mental health**, rather than solely aiming for weight loss on the scale. ### 4. **New Pharmacotherapy Options** - Two new medications have been introduced: - **Tirzepatide**: A GLP-1/GIP dual agonist with strong evidence for significant and sustained weight loss. - **Setmelanotide**: Targeted specifically for rare genetic forms of obesity. - These drugs complement existing options like **semaglutide**, which has already demonstrated efficacy in weight management. ### 5. **Integration with Behavior Change** - Pharmacotherapy is explicitly recommended as part of a broader strategy that includes **behavioral interventions** like improved nutrition, increased physical activity, and psychosocial support. - The guidelines stress that medication should not be used in isolation. ### 6. **Focus on Obesity-Related Complications** - The guidelines expand recommendations for using pharmacotherapy in individuals with obesity-related health conditions, including: - **Cardiovascular disease** - **Heart failure** - **Prediabetes** - **Obstructive sleep apnea** - **Osteoarthritis** - This approach aims to prevent long-term complications and reduce morbidity and mortality associated with excess adiposity. ### 7. **Evidence-Based Recommendations** - The updates are based on a thorough review of scientific literature from 2022–2024, supplemented by clinical trials up to May 2025. - The guidelines are aligned with international standards, such as those in the U.S. and Europe, which increasingly emphasize pharmacotherapy as a central component of obesity care. ### 8. **Safety and Efficacy** - The guidelines caution against the use of **compounded weight-loss medications** or **off-label use of drugs not approved for obesity treatment**, citing concerns about safety and efficacy. - Only medications with robust clinical trial data should be used. ### 9. **Primary Care’s Role** - Primary care physicians are highlighted as critical in identifying candidates for pharmacotherapy, initiating treatment, and providing follow-up care. - This underscores the need for primary care providers to be well-versed in the updated guidelines. ### 10. **Ethnicity-Specific and Equity Considerations** - The guidelines acknowledge that BMI thresholds and risk profiles vary across different ethnic groups. - This ensures that treatment decisions are more equitable and biologically appropriate for diverse populations. ### 11. **Patient Involvement in Guideline Development** - People with lived experience of obesity were actively involved in shaping the recommendations. - This ensures that the guidelines address real-world needs and align with patient priorities. ### 12. **Shift Away from Weight Stigma** - The guidelines shift the focus from weight-loss-only goals to broader health outcomes, such as improving comorbidities and enhancing overall health functioning. - This approach aims to reduce weight stigma in healthcare settings. ### 13. **Public Health and System Support** - With obesity rates rising in Canada, the guidelines are positioned as a critical tool to improve access to evidence-based treatments. - Experts stress the need for government and healthcare systems to provide coverage and resources to make these treatments widely accessible. ### 14. **Prevention of Long-Term Complications** - By addressing high-risk groups (e.g., those with prediabetes or cardiovascular disease), the recommendations aim to prevent the progression of obesity-related complications and improve long-term outcomes. ### 15. **Consistency with Global Trends** - The Canadian guidelines align with global trends, emphasizing pharmacotherapy as a key component of obesity management, alongside behavioral and surgical interventions. ### 16. **Key Takeaway** - Obesity is recognized as a **chronic and complex disease** requiring tailored, evidence-based, and multidisciplinary treatment. - Pharmacotherapy is an integral part of long-term obesity management, but it must always be combined with lifestyle and psychological support for optimal outcomes. ### Implications for the Future: - The updated guidelines reflect a growing recognition of the importance of treating obesity as a medical condition rather than a lifestyle choice. - They also highlight the need for healthcare systems to adapt and provide equitable access to effective treatments, ensuring that more individuals benefit from these advancements. These guidelines represent a major step forward in addressing the obesity epidemic in Canada, offering a structured framework for evidence-based, patient-centered care.

GLP-1 therapy with nutrition and lifestyle guidance

GLP-1 therapy, such as medications like semaglutide and tirzepatide, has emerged as a powerful tool for weight management and metabolic health improvement. However, it is not a standalone solution for long-term success. To achieve optimal results, GLP-1 therapy must be paired with comprehensive nutrition and lifestyle guidance. Here's a detailed breakdown of how these components work together: ### 1. **Weight Loss with GLP-1 Therapy** - GLP-1 medications can induce significant weight loss, typically in the range of 15–22%. However, the degree of weight loss varies by individual and depends heavily on adherence to a healthy lifestyle and dietary habits. - These medications work by suppressing appetite, slowing gastric emptying, and improving insulin sensitivity, but they are most effective when combined with behavioral changes. ### 2. **Metabolic and Systemic Health Benefits** - Beyond weight loss, GLP-1 therapies improve markers of metabolic health, including: - Lowering LDL cholesterol and triglycerides - Raising HDL cholesterol - Reducing blood pressure - Improving blood glucose levels and cardiovascular outcomes - Alleviating arthritis pain, sleep apnea, and even fibrosis in metabolic-associated steatohepatitis (MASH) - These benefits highlight the systemic impact of GLP-1 medications on overall health. ### 3. **Comprehensive Patient Evaluation** - Before initiating GLP-1 therapy, clinicians must conduct a thorough assessment, including: - Weight history and previous attempts at weight loss - Screening for eating disorders, as appetite-suppressing medications may not be appropriate for individuals with these conditions - Mood disorder evaluation, since depression and anxiety can either improve or worsen with weight loss - Sarcopenia risk assessment, as rapid weight loss can lead to lean mass loss, particularly in older adults or those with chronic illnesses ### 4. **Nutrition Guidance** - **Dietary Recommendations**: A nutrient-dense diet is essential to support health during weight loss. Recommended foods include: - Fruits, vegetables, whole grains, legumes, lean proteins, nuts, and seeds - Limiting processed and high-fat foods - **Protein Intake**: Protein is critical for preserving muscle mass during weight loss. Patients should aim to consume approximately 0.4–0.5 grams of protein per pound of body weight daily. For example, a 200-pound adult should target 70–80 grams of protein per day. - Practical protein sources: Greek yogurt, eggs, fish, chicken, protein shakes, nuts, and seeds - **Supplementation**: Due to reduced food intake, patients may be at risk for nutritional deficiencies, particularly in Vitamin D, calcium, and B12. A daily multivitamin with minerals can help address these needs. ### 5. **Lifestyle Guidance** - **Exercise**: Physical activity is indispensable for preserving muscle and bone health during weight loss. Recommendations include: - Strength training at least 3 times per week - 150 minutes of moderate-intensity aerobic exercise weekly - Weight-bearing and resistance exercises to support bone density - **Hydration**: Appetite suppression from GLP-1s can blunt thirst, so patients must consciously hydrate, especially in hot weather. ### 6. **Managing Side Effects** - **Gastrointestinal (GI) Issues**: Up to one-third of patients experience nausea, vomiting, diarrhea, or constipation during the first 1–3 months of therapy. Practical tips include: - Eating small, frequent meals - Avoiding fatty foods - Eating slowly and stopping when full - **Medication Support**: Slower titration of the GLP-1 dose can reduce GI side effects. Anti-nausea medications (e.g., ondansetron, prochlorperazine) and constipation remedies (e.g., fluids, fiber, polyethylene glycol) may also help. ### 7. **Long-Term Considerations** - **Muscle Loss**: Rapid weight loss can lead to lean mass loss (up to 25% of weight lost). This is not caused by GLP-1 therapy itself but rather by the speed of the weight loss. Proper protein intake and exercise are critical to mitigate this. - **Bone Health**: While GLP-1s may protect bone density, rapid weight loss can reduce it. Resistance and weight-bearing exercises are essential to counteract this effect. - **Weight Regain After Discontinuation**: Without sustainable habits, most patients regain weight after stopping GLP-1 therapy. This regain is often primarily fat rather than muscle if exercise is not maintained. ### 8. **Holistic Treatment Approach** - The best outcomes with GLP-1 therapy occur when patients adopt sustainable habits in diet and exercise while on the medication. Clinicians play a key role in guiding patients to: - Build a balanced, nutrient-dense diet - Incorporate regular physical activity - Monitor mood and mental health - Address side effects and nutritional deficiencies proactively - The goal is to help patients retain the health gains achieved during therapy and prevent weight regain in the long term. In summary, GLP-1 therapy is a highly effective tool for weight loss and metabolic health improvement, but it must be part of a comprehensive approach that includes tailored nutrition, exercise, and lifestyle guidance. By addressing these factors holistically, patients can achieve sustainable health outcomes and enhance their quality of life.

Mental health, emotional eating, lifestyle factors, and BMI trajectories

The relationship between mental health, emotional eating, lifestyle factors, and BMI (Body Mass Index) trajectories is intricate and multifaceted, as highlighted by the study summarized in the context. Below is a detailed exploration of these interconnected elements: ### 1. **Bidirectional Relationship Between Mental Health and BMI** - The study confirms a **two-way relationship** between obesity and poor mental health, such as depression and anxiety. This means that poor mental health can lead to weight gain, and conversely, obesity can exacerbate mental health conditions. - The longitudinal nature of the study (tracking participants over 4 years) provides stronger evidence of causality, unlike previous cross-sectional studies. ### 2. **Role of Emotional Eating** - **Emotional eating** is a key mediator linking poor mental health (e.g., depression and anxiety) to weight gain. Emotional eating refers to the tendency to consume food in response to emotional distress rather than physical hunger. - This behavior is particularly pronounced among women, suggesting **gender-specific vulnerabilities** in how emotional eating impacts BMI. - Emotional eating is also exacerbated by **physical inactivity**, creating a compounded risk for weight gain. ### 3. **Psychosocial and Financial Stressors** - **Financial hardship**, loneliness, and baseline depressive or anxiety symptoms were significant predictors of BMI gain. These factors highlight the **socioeconomic dimension** of obesity and how stress-driven behaviors (like emotional eating) can contribute to weight gain. - Emotional eating partially mediated the link between financial stress and BMI increase, suggesting that stress-induced eating habits are a major pathway. ### 4. **Lifestyle Factors Impacting BMI** - Several lifestyle behaviors were associated with increasing BMI over time: - **Physical inactivity:** Lack of exercise amplifies the impact of emotional eating on weight gain. - **Poor diet:** Low intake of fruits and vegetables contributes to unhealthy weight trajectories. - **Leisure screen time:** Increased screen time is strongly correlated with weight gain, likely due to sedentary behavior and snacking. - **Short sleep duration:** Poor sleep is a significant risk factor for higher BMI, aligning with its effects on metabolism and appetite regulation. ### 5. **Antidepressant Use and Weight Gain** - The study found that the use of antidepressant medications was associated with increased BMI. This is consistent with known side effects of certain antidepressants, which can lead to weight gain. ### 6. **Body Image and Quality of Life** - Weight gain and rising BMI were linked to **body dissatisfaction**, which can perpetuate a negative cycle of emotional eating and psychological stress. - Higher BMI was also associated with **lower overall quality of life**, particularly when mediated by poor self-rated health and body dissatisfaction. ### 7. **Mental Health Outcomes and BMI** - Interestingly, while poor mental health (e.g., depression and anxiety) predicted weight gain, increasing BMI did not directly predict worsening mental health at follow-up after adjusting for baseline levels. This indicates that the relationship is not entirely linear and is influenced by mediating factors like emotional eating and body dissatisfaction. ### 8. **Vicious Cycle of Mental Health and Weight Gain** - The study describes a **complex and self-reinforcing cycle**: - Anxiety and depression lead to emotional eating. - Emotional eating contributes to weight gain. - Weight gain results in body dissatisfaction. - Body dissatisfaction reduces quality of life, which can further exacerbate mental health issues. - This cycle underscores the interconnectedness of mental health, emotional eating, and BMI trajectories. ### 9. **Policy and Clinical Implications** - **Policy Recommendations:** - Financial support and mental health care access are critical for addressing the socioeconomic and psychological dimensions of obesity. - Promotion of healthier lifestyles, including improved diet, physical activity, and sleep hygiene, can help break the cycle of weight gain and poor mental health. - **Clinical Takeaways:** - Emotional eating should be directly addressed in interventions for individuals with depression and anxiety to prevent weight gain. - Holistic strategies targeting modifiable risk factors—such as emotional eating, diet, exercise, sleep, and stress management—are essential for effective obesity prevention and treatment. ### 10. **Key Modifiable Risk Factors** - The study emphasizes that focusing solely on calorie restriction is insufficient for managing obesity. Instead, addressing the following modifiable factors is crucial: - **Emotional eating**: Helping individuals develop healthier coping mechanisms for stress and emotional distress. - **Diet**: Encouraging balanced eating habits with adequate fruit and vegetable intake. - **Exercise**: Promoting regular physical activity to counteract sedentary behaviors. - **Sleep**: Improving sleep duration and quality to support metabolic health. - **Stress management**: Reducing financial and psychosocial stress to minimize stress-driven eating behaviors. In conclusion, the study highlights the intricate interplay between mental health, emotional eating, lifestyle factors, and BMI trajectories. It underscores the importance of addressing these factors holistically to prevent and treat obesity while improving overall mental and physical well-being.

Canadian guideline on managing obesity in children and adolescents

The Canadian guideline on managing obesity in children and adolescents represents a landmark shift in addressing pediatric obesity as a chronic disease. It is the first dedicated guideline for childhood and adolescent obesity in Canada, separate from the adult-focused guideline released nearly 20 years ago. Below is a detailed overview of the key aspects of this guideline: ### 1. **Prevalence and Context** - Pediatric obesity is a significant health concern in Canada, affecting **1 in 4 children under 11 years** and **1 in 3 adolescents aged 12–17 years**. - Globally, the prevalence of pediatric obesity has **tripled over the past 30 years**, making it a growing public health challenge. ### 2. **Framing Obesity as a Chronic Disease** - The guideline emphasizes that pediatric obesity is a **chronic, stigmatized, and progressive disease** requiring **long-term management** rather than short-term interventions. - This approach aligns with the recognition of obesity as a chronic disease by 74 scientific societies globally, though only Alberta in Canada has officially adopted this definition. ### 3. **Core Recommendations** The guideline outlines **10 recommendations**, which are divided into three categories: - **Behavioral/Psychological Interventions (5 recommendations)**: These are the first-line treatments, focusing on lifestyle modifications and psychological support to achieve sustainable health improvements. - **Pharmacologic Interventions (3 recommendations)**: Medications are now suggested as an option for older children (≥12 years), but always in combination with behavioral therapy. Early use of pharmacotherapy is encouraged to prevent long-term complications. - **Surgical Interventions (2 recommendations)**: Bariatric surgery is recognized as an option for adolescents with severe obesity when other measures fail, based on growing evidence of its safety and effectiveness. ### 4. **Holistic and Patient-Centered Care** - The guideline moves away from weight-loss-centric goals and instead focuses on **improving physical health, mental health, and overall well-being**. - Families and caregivers were actively involved in shaping the guideline, ensuring a **family-centered and patient-prioritized approach**. - Families emphasized that **health-related quality of life, anxiety, and mental health outcomes** were more important than weight loss, waist circumference, or lab results. ### 5. **Behavioral Interventions as First-Line Treatment** - Lifestyle modifications and psychological support are considered the **cornerstone of treatment**, with the aim of achieving sustainable improvements in health outcomes. - A **family-centered approach** is critical, with parents and caregivers playing an integral role in the treatment process. ### 6. **Integration of Mental Health** - The guideline highlights the importance of addressing **anxiety, depression, and psychosocial well-being**, recognizing the psychological burden of pediatric obesity. - Mental health outcomes are considered central to the success of obesity management programs. ### 7. **Pharmacotherapy** - Medications are recommended as an option for older children (≥12 years) with obesity, but only in combination with behavioral therapy. - The guideline advises against delaying pharmacologic interventions unnecessarily, as early treatment may help prevent long-term complications. ### 8. **Surgical Options** - Bariatric surgery is recognized as a viable option for adolescents with **severe obesity** when other treatment measures fail. - The guideline reflects growing evidence supporting the **safety and effectiveness** of bariatric surgery in adolescents. ### 9. **Scientific Consensus and Policy Gaps** - While there is scientific consensus globally on obesity being a chronic disease, Canada lags behind in policy recognition, with only Alberta officially recognizing pediatric obesity as such. - This lack of systemic recognition hinders the prioritization of funding and policy action. ### 10. **Health System Challenges** - Most pediatric obesity clinics in Canada rely on grants and personal funding, highlighting the need for **sustained government support** to implement the guideline effectively. - Without systemic funding, access to multidisciplinary obesity care remains uneven, exacerbating **health disparities** among children. ### 11. **Cultural and Paradigm Shift** - The guideline represents a **paradigm shift** in pediatric obesity management, moving away from BMI-centric goals and focusing on **function, mental health, and quality of life**. - This cultural shift aims to reduce stigma and foster a more compassionate approach to managing obesity. ### 12. **Stakeholder Engagement** - The guideline was developed with input from healthcare providers, parents, and caregivers to ensure it reflects **real-world needs** and is grounded in **patient-centered care**. ### 13. **Advocacy for Recognition and Support** - Experts argue that obesity must be recognized as the **most prevalent chronic disease in Canadian children** to secure funding and drive policy action. - A **multidisciplinary, government-supported approach** is essential for effective implementation of the guideline. ### 14. **Industry Disclosures** - Some authors of the guideline reported financial ties to pharmaceutical companies involved in obesity treatments, while others had no conflicts of interest. ### **Overall Message** The Canadian guideline calls for a **holistic, family-centered, multidisciplinary approach** to managing pediatric obesity. It emphasizes the importance of **psychological well-being, early intervention**, and a shift away from weight-centric goals toward improving overall health and quality of life. It also highlights the need for sustained government support to ensure equitable access to effective obesity care across Canada.